<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02819726</url>
  </required_header>
  <id_info>
    <org_study_id>AGB001</org_study_id>
    <nct_id>NCT02819726</nct_id>
  </id_info>
  <brief_title>PK, PD, Safety, and Efficacy of SAIT101 Versus MabThera® Versus Rituxan® in Patients With Rheumatoid Arthritis</brief_title>
  <official_title>A Randomized, Double-blind, Parallel Group, Multicenter Study to Compare the Pharmacokinetics, Pharmacodynamics, Safety, and Efficacy of SAIT101 Versus MabThera® Versus Rituxan® in Patients With Rheumatoid Arthritis (RA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Archigen Biotech Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Archigen Biotech Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomised, double blind, parallel group, multicentre study yo compare the
      pharmacokinetics, pharmacokinetics, safety and efficacy of SAIT101 versus MabThera® versus
      Rituxan® in patients with rheumatoid arthritis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, parallel group, multicenter study to compare the
      pharmacokinetics (PK), pharmacodynamics (PD), safety, efficacy, tolerability, and
      immunogenicity of SAIT101 (biosimilar rituximab) versus MabThera® versus Rituxan® in patients
      with rheumatoid arthritis (RA). This study will take place globally across approximately 75
      study centers in order to randomize approximately 282 patients. The study consists of Part A
      from baseline for PK and efficacy analysis, followed by Part B from Week 24 to 52 for safety
      follow-up in which collects transition data.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 11, 2016</start_date>
  <completion_date type="Actual">November 7, 2018</completion_date>
  <primary_completion_date type="Actual">April 30, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>In Part A, patients are randomized in a 1:1:1 ratio to receive one course (baseline and Week 2) of SAIT101 (n=94) versus Rituxan® (n=94) versus MabThera® (n=94).
At Week 24, patients are evaluated for the second course (Week 24 and 26) of the infusion.
In Part B, eligible patients in the SAIT101 arm receive the second course of SAIT101 treatment. Eligible patients in the MabThera® arm receive the second course of MabThera® treatment. Eligible patients in the Rituxan® arm are randomized in a 1:1 ratio to receive SAIT101 or Rituxan® treatment. Patients are followed up for safety until Week 52.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Concentration Time Cure From Time 0 to Last Quantifiable Concentration (AUC0-t)</measure>
    <time_frame>Samples for pharmacokinetic evaluation were taken at Baseline and Weeks 0, 1, 2, 3, 4, 8, 12, 16, 20 and 24. Unscheduled visit samples were taken at the discretion of the investigator.</time_frame>
    <description>Pharmacokinetic endpoint: Area under the concentration-time curve from time 0 (immediately predose on Day 1) to last quantifiable concentration (AUC0-t). Geometric means by treatment (Pharmacokinetic Analysis Set).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration Versus Time Curve (AUC0-∞)</measure>
    <time_frame>Samples for pharmacokinetic evaluation were taken at Baseline and Weeks 0, 1, 2, 3, 4, 8, 12, 16, 20 and 24. Unscheduled visit samples were taken at the discretion of the investigator.</time_frame>
    <description>Pharmacokinetic endpoint: Area Under the Plasma Concentration from time 0 to infinity (AUC0-∞ (infinity). Calculated by linear up/log down trapezoidal summation and extrapolated to infinity by addition of the last quantifiable concentration divided by the elimination rate constant: AUC(0-last) + C(last)/λz.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration Versus Time Curve (AUC0-D15)</measure>
    <time_frame>Samples for pharmacokinetic evaluation were taken at Baseline and Weeks 0, 1, 2, 3, 4, 8, 12, 16, 20 and 24. Unscheduled visit samples were taken at the discretion of the investigator.</time_frame>
    <description>Pharmacokinetic endpoint: Area Under the Concentration verses time from time 0 to Day 15 prior to infusion (AUC0-D15) calculated by linear up/log down trapezoidal summation. Actual time/concentration on Day 15 was used for the calculation of this parameter unless the parameter was derived by interpolation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak Plasma Concentration (Cmax) After Day 15 Infusion</measure>
    <time_frame>Samples for pharmacokinetic evaluation were taken at Baseline and Weeks 0, 1 and 2 (Pre-dose 2). Unscheduled visit samples were taken at the discretion of the investigator.</time_frame>
    <description>Pharmacokinetic endpoint: Maximum Plasma Concentration (Cmax) after Day 15 infusion (Dose 2)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Trough Concentration (Ctrough) Before the Second Infusion on Day 15</measure>
    <time_frame>Samples for pharmacokinetic evaluation were taken at Baseline and Weeks 0, 1 and 2 (Pre-dose 2). Unscheduled visit samples were taken at the discretion of the investigator.</time_frame>
    <description>Pharmacokinetic endpoint: Trough concentration (Ctrough) before the second infusion on Day 15 (Dose 2). Trough (pre-dose) concentration prior to second infusion on Day 15 obtained directly from the observed concentration versus time data.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in DAS28-CRP at Week 24</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>Disease Activity Score 28 C-reactive protein score (DAS28-CRP) at Week 24 (Full Analysis Set). CRP samples were collected at Baseline and Weeks 8, 16 and 24. DAS28-CRP was calculated using the following equation: [0.56*Square Root (SQRT) (tender 28 joint count)+0.28*SQRT(swollen 28 joint count)+0.36*ln(CRP+1)]*1.10+1.15.
Total DAS28-CRP scores were calculates and range from 2.0 (minimum) to 10 (maximum). Lower scores represent a better patient outcome. Disease remission is considered achieved if the score is between 0 and &lt;2.6. Low disease activity corresponds to 2.6 to &lt;3.2. Moderate activity is between 3.2 &amp; ≤5.1, while high activity is above 5.1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration Time Curve Week 2 to Week 24 (AUC(w2-24)</measure>
    <time_frame>Samples for pharmacokinetic evaluation were taken at Baseline and Weeks 0, 1, 2, 3, 4, 8, 12, 16, 20 and 24. Unscheduled visit samples were taken at the discretion of the investigator.</time_frame>
    <description>Pharmacokinetic endpoint: Area under the concentration time curve week 2 to week 24 (AUC(w2-24) calculated by linear up/log down trapezoidal summation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration Time Curve Day 0 to Week 12 (AUC(0-w12))</measure>
    <time_frame>Samples for pharmacokinetic evaluation were taken at Baseline and Weeks 0, 1, 2, 3, 4, 8 and 12. Unscheduled visit samples were taken at the discretion of the investigator.</time_frame>
    <description>Pharmacokinetic endpoint: Area under the concentration time curve Day 0 to Week 12 calculated by linear up/log down trapezoidal summation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Plasma Concentration (Tmax) (Dose 1)</measure>
    <time_frame>Samples for pharmacokinetic evaluation were taken at Baseline and Weeks 0, 1, 2, 3, 4, 8, 12, 16, 20 and 24. Unscheduled visit samples were taken at the discretion of the investigator.</time_frame>
    <description>Pharmacokinetic endpoint: Maximum plasma concentration over the first dosing interval obtained directly from the observed concentration versus time data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Plasma Concentration (Tmax) (Dose 2)</measure>
    <time_frame>Samples for pharmacokinetic evaluation were taken at Baseline and Weeks 0, 1, 2, 3, 4, 8, 12, 16, 20 and 24. Unscheduled visit samples were taken at the discretion of the investigator.</time_frame>
    <description>Time of maximum concentration postinfusion over the second dosing interval, obtained directly from the observed concentration versus time data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Terminal Rate Constant (λz)</measure>
    <time_frame>Samples for pharmacokinetic evaluation were taken at Baseline and Weeks 0, 1, 2, 3, 4, 8, 12, 16, 20 and 24. Unscheduled visit samples were taken at the discretion of the investigator.</time_frame>
    <description>Pharmacokinetic endpoint: Apparent terminal rate constant (λz) determined by linear regression of the terminal points of the log-linear concentration-time curve. Best fit method followed by visual assessment was used to identify the terminal linear phase of the concentration-time profile. A minimum of 3 data points was used for determination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic Clearance (CL)</measure>
    <time_frame>Samples for pharmacokinetic evaluation were taken at Baseline and Weeks 0, 1, 2, 3, 4, 8, 12, 16, 20 and 24. Unscheduled visit samples were taken at the discretion of the investigator.</time_frame>
    <description>Pharmacokinetic endpoint: Systemic clearance (CL) over the first dosing period calculated as dose (first + second dose) divided by AUC(0-∞).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of Distribution (VD)</measure>
    <time_frame>Samples for pharmacokinetic evaluation were taken at Baseline and Weeks 0, 1, 2, 3, 4, 8, 12, 16, 20 and 24. Unscheduled visit samples were taken at the discretion of the investigator.</time_frame>
    <description>Pharmacokinetic endpoint: Volume of distribution (VD) over the first dosing period calculated as dose (first + second dose) divided by [λz AUC(0-∞)]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Half-life (T1/2)</measure>
    <time_frame>Samples for pharmacokinetic evaluation were taken at Baseline and Weeks 0, 1, 2, 3, 4, 8, 12, 16, 20 and 24. Unscheduled visit samples were taken at the discretion of the investigator.</time_frame>
    <description>Pharmacokinetic endpoint: Terminal half-life determined as ln2/λz.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in DAS28-CRP at Weeks 8, 16, 36 and 52</measure>
    <time_frame>Baseline and Weeks 8, 16, 24, 36 and 52 (EOS)</time_frame>
    <description>Disease Activity Score 28-C-Reactive Protein (DAS28-CRP) samples taken at Baseline and Weeks 8, 16, 24, 36 and 52. DAS28-CRP was calculated using the following equation: [0.56*Square Root (SQRT) (tender 28 joint count)+0.28*SQRT(swollen 28 joint count)+0.36*ln(CRP+1)]*1.10+1.15.
Total DAS28-CRP scores are presented and range from 2.0 (minimum) to 10 (maximum). Lower scores represent a better patient outcome. Disease remission is considered achieved if the score is between 0 and &lt;2.6. Low disease activity corresponds to 2.6 to &lt;3.2. Moderate activity is between 3.2 &amp; ≤5.1, while high activity is above 5.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>American Collage of Rheumatology 20% Response Criteria (ACR20) Response Rates at Weeks 8, 16, 24, 36 and 52</measure>
    <time_frame>Baseline and Weeks 8, 16, 24, 36 and 52 (EOS)</time_frame>
    <description>American Collage of Rheumatology (ACR) 20% response criteria (ACR20) response rates were assessed at Baseline and Weeks 8, 16, 24, 36 and 52.
An ACR20 response is defined as both improvement of 20% in the number of tender and number of swollen joints, and a 20% improvement in three of the following five criteria: patient global assessment, physician global assessment, functional ability measure [Health Assessment Questionnaire (HAQ)], visual analogue pain scale, and erythrocyte sedimentation rate or C-reactive protein (CRP).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>American Collage of Rheumatology 50% Response Criteria (ACR50) Response Rates and American Collage of Rheumatology 70% Response Criteria (ACR70) at Weeks 8, 16, 24, 36 and 52</measure>
    <time_frame>Baseline and Weeks 8, 16, 24, 36 and 52 (EOS)</time_frame>
    <description>Efficacy endpoint: American Collage of Rheumatology 50% response criteria (ACR50) response rates and American Collage of Rheumatology 70% response criteria (ACR70) at weeks 8, 16, 24, 36 and 52.
An ACR50 response is defined as both improvement of 50% in the number of tender and number of swollen joints, and a 50% improvement in three of the following five criteria: patient global assessment, physician global assessment, functional ability measure [Health Assessment Questionnaire (HAQ)], visual analogue pain scale, and erythrocyte sedimentation rate or C-reactive protein (CRP).
An ACR70 response is defined as both improvement of 70% in the number of tender and number of swollen joints, and a 70% improvement in three of the following five criteria: patient global assessment, physician global assessment, functional ability measure [Health Assessment Questionnaire (HAQ)], visual analogue pain scale, and erythrocyte sedimentation rate or C-reactive protein (CRP).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Individual Components of the ACR Improvement Criteria on Day 1 and at Weeks 8, 16, 24, 36 and 52: Swollen Joint Count (SJC) and Tender Joint Count (TJC) (the 66/68 Joint Count System)</measure>
    <time_frame>Baseline and Weeks 8, 16, 24, 36 and 52 (EOS)</time_frame>
    <description>Efficacy endpoint: Individual components of the ACR improvement criteria on Day 1 and at weeks 8, 16, 24, 36 and 52: Swollen Joint Count (SJC) and tender joint count (TJC) (the 66/68 joint count system). SJC and TJC assess the level of skeletal disease involvement. The 66/68 Joint Count evaluates 66 joints for swelling and 68 joints for tenderness.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Individual Components of the ACR Improvement Criteria on Day 1 and at Weeks 8, 16, 24, 36 and 52: Physicians Global Assessment of Disease Activity (Assessed on 1 to 100 mm Visual Analog Scale [VAS])</measure>
    <time_frame>Baseline and Weeks 8, 16, 24, 36 and 52 (EOS)</time_frame>
    <description>Efficacy endpoint: Individual Components of the ACR Improvement Criteria on Day 1 and at Weeks 8, 16, 24, 36 and 52: Physicians global assessment of disease activity (assessed on 1 to 100 mm Visual Analog Scale [VAS]). Where 0 = no disease activity and 100 = maximum disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Individual Components of the ACR Improvement Criteria on Day 1 and at Weeks 8, 16, 24, 36 and 52: Participants Assessment of Pain (Assessed on 1 to 100 mm Visual Analog Scale [VAS])</measure>
    <time_frame>Baseline and Weeks 8, 16, 24, 36 and 52 (EOS)</time_frame>
    <description>Participants assessment of pain (assessed on 1 to 100 mm Visual Analog Scale [VAS]). Participants assessment of pain (assessed on 1 to 100 mm Visual Analog Scale [VAS]) where 0 = no pain and 100 = severe pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Individual Components of the ACR Improvement Criteria on Day 1 and at Weeks 8, 16, 24, 36 and 52: Participants Global Assessment of Disease Activity (Assessed on 1 to 100 mm VAS)</measure>
    <time_frame>Baseline and Weeks 8, 16, 24, 36 and 52 (EOS)</time_frame>
    <description>Efficacy endpoint: Individual Components of the ACR Improvement Criteria on Day 1 and at Weeks 8, 16, 24, 36 and 52: Participants global assessment of disease activity (assessed on 1 to 100 mm visual analogue scale [VAS]). Patients rate how their Rheumatoid Arthritis has affected them, where 0 = very well and 100 = very poor.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Individual Components of the ACR Improvement Criteria on Day 1 and at Weeks 8, 16, 24, 36 and 52: Participants Assessment of Disability (Health Assessment Questionnaire-Disability Index [HAQ-DI])</measure>
    <time_frame>Baseline and Weeks 8, 16, 24, 36 and 52 (EOS)</time_frame>
    <description>the Health Assessment Questionnaire-Disability Index (HAQ-DI) contains 20 questions split into 8 categories (dressing &amp; grooming, arising, eating, walking, hygiene, reach, grip &amp; activities). Scores were: 0 = Without ANY Difficulty; 1 = With SOME Difficulty; 2 = With MUCH Difficulty; 3 = UNABLE to Do. Total scores were calculated as the summed category scores divided by the number of categories.
Total HAQ-DI scores are presented which range from 0 to 3. Higher scores represent a worse outcome. Scores of 0 to 1 represent mild to moderate difficulty, 1 to 2 moderate disability, and 2 to 3 severe to very severe disability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Individual Components of the ACR Improvement Criteria on Day 1 and at Weeks 8, 16, 24, 36 and 52: C-reactive Protein (CRP) Level</measure>
    <time_frame>Baseline and Weeks 8, 16, 24, 36 and 52 (EOS)</time_frame>
    <description>C-reactive protein (CRP) level (Mg/L). CRP is a marker for inflammation. a normal reading is &lt;3 Mg/L. Higher values indicate disease related inflammation and increased cardiovascular risk.
CRP levels between 3 Mg/L and 10 Mg/L are mildly elevated. Levels between 10 Mg/L and 100 Mg/L are moderately elevated and CRP levels above 100 Mg/L are severely elevated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline DAS28-erythrocyte Sedimentation Rate (ESR) at Weeks 8, 16, 24, 36 and 52</measure>
    <time_frame>Baseline and Weeks 8, 16, 24, 36 and 52 (EOS)</time_frame>
    <description>Disease Activity Score 28- Erythrocyte Sedimentation Rate (DAS28-ESR) consisted of tender joint counts (TJC), swollen joint counts (SJC) &amp; erythrocyte sedimentation rate (ESR). The formula is: [0.56*SQRT(tender 28 joint count)+0.28*SQRT(swollen 28 joint count)+0.7*ln(ESR)]+0.014*patient global health assessment.
Total DAS28-ESR scores are presented. Total scores range from 2 (minimum) to 10 (maximum). A lower score represents a better patient outcome. A DAS28-ESR of greater than 5.1 implies active disease, less than 3.2 low disease activity, and less than 2.6 remission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With a Major Clinical Response (Continuous ACR70) for at Least 24 Weeks</measure>
    <time_frame>Baseline and Weeks 8, 16, 24, 36 and 52 (EOS)</time_frame>
    <description>Efficacy endpoint: number of participants with a major clinical response defined as a continuous ACR70 from Baseline (Day 1) for at least 24 weeks.
ACR70 is a measure based on American College of Rheumatology criteria of at least a 70% improvement in the number of tender and swollen joints, and a 70% improvement in at least 3 of the following: the patient's global assessment of disease status; the patient's assessment of pain; the patient's assessment of function measured using the Stanford Health Assessment Questionnaire the physician's global assessment of disease status; serum C-reactive protein levels.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With a Clinical Remission Response (CRR) at Weeks 8, 16, 24, 36 and 52</measure>
    <time_frame>Baseline and Weeks 8, 16, 24, 36 and 52 (EOS)</time_frame>
    <description>Number if Participants with a Clinical Remission Response (CRR) defined by the Simplified Disease Activity Index (SDAI) &lt;3.3 at weeks 8, 16, 24, 36 and 52 (EOS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With European League Against Rheumatism (EULAR) Response at Weeks 8, 16, 24 36 and 52</measure>
    <time_frame>Baseline and Weeks 8, 16, 24, 36 and 52 (EOS)</time_frame>
    <description>Efficacy endpoint: Proportion of participants with European League Against Rheumatism (EULAR) response (defined as good response, moderate response or no response) at weeks 8, 16, 24 36 and 52 (EOS). EULAR (European League Against Rheumatism) response was classified using the individual amount of change in the DAS28-CRP score. The DAS28-CRP was classified into 3 categories: low disease activity (&lt;= 3.2), moderate disease activity (&gt; 3.2 and &lt;= 5.1) and high disease activity (&gt; 5.1). Good response was defined as &gt;1.2 improvement in the DAS28-CRP from baseline with low disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic Endpoint: Change From Baseline in Immunoglobulin (IgG, IgM and IgA Levels)</measure>
    <time_frame>Baseline (Day 1) and Weeks 8, 16, 24, 36 and 52 (EOS)</time_frame>
    <description>Change from baseline (Day 1) in immunoglobulin G (IgG), Immunoglobulin M (IgM) and Immunoglobulin A (IgA) levels (mg/dL) at Week 8, 16, 24 36 and 52 (End of study)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Pharmacodynamic Endpoint: Depletion of B-lymphocyte Antigen CD19 (CD19+) B-cell Count up to Week 24</measure>
    <time_frame>Samples for pharmacodynamic evaluation (CD19+ B-cell) were taken at Baseline and Weeks 0, 1, 2, 3, 4, 8, 12, 16, 20 and 24. Unscheduled visit samples were taken at the discretion of the investigator.</time_frame>
    <description>Pharmacodynamic endpoint: proportion of participants (n) with depletion of CD19+ B-cell count up to week 24 (Pharmacodynamic analysis set).</description>
  </other_outcome>
  <other_outcome>
    <measure>Pharmacodynamic Endpoint: Time Needed to CD19+ B-cell Depletion</measure>
    <time_frame>Samples for pharmacodynamic evaluation (CD19+ B-cell) were taken at Baseline and Weeks 0, 1, 2, 3, 4, 8, 12, 16, 20, 24, 36 and 52. Unscheduled visit samples were taken at the discretion of the investigator.</time_frame>
    <description>Time needed to CD19+ B-cell depletion in Part A (calculated as the first time CD19+ B-cell count below 20/µL minus time of first dosing in days).</description>
  </other_outcome>
  <other_outcome>
    <measure>Pharmacodynamic Endpoint: Duration of CD19+ B-cell Depletion</measure>
    <time_frame>Samples for pharmacodynamic evaluation (CD19+ B-cell) were taken at Baseline and Weeks 0, 1, 2, 3, 4, 8, 12, 16, 20, 24, 36 and 52. Unscheduled visit samples were taken at the discretion of the investigator.</time_frame>
    <description>Duration of CD19+ B-cell depletion (only participants that returned to non-depletion at or before week 24 were included)</description>
  </other_outcome>
  <other_outcome>
    <measure>Pharmacodynamic Endpoint: Number of Participants With CD19+ B-cell Count Recover Versus Baseline</measure>
    <time_frame>Samples for pharmacodynamic evaluation (CD19+ B-cell) were taken at Baseline and Weeks 0, 1, 2, 3, 4, 8, 12, 16, 20, 24, 36 and 52. Unscheduled visit samples were taken at the discretion of the investigator.</time_frame>
    <description>Number of participants with CD19+ B-cell count recover versus baseline. Incidence of B-Cell recovery was defined as either CD19+ B-cell counts retuned to baseline or the lower limit or normal of 110 cells/µL at week 24).</description>
  </other_outcome>
  <other_outcome>
    <measure>Pharmaco Endpoint: Area Under the Concentration Time Curve of CD19 B-cell Count Change at Day 15 and Week 24</measure>
    <time_frame>Samples for pharmacodynamic evaluation (CD19+ B-cell) were taken at Baseline and Weeks 0, 1, 2, 3, 4, 8, 12, 16, 20, 24, 36 and 52. Unscheduled visit samples were taken at the discretion of the investigator.</time_frame>
    <description>Area under the concentration time curve of CD19 B-cell count change at Day 15 (AUEC0-d15) and week 24 (AUEC0-w24) based on change from baseline and percent of baseline values</description>
  </other_outcome>
  <other_outcome>
    <measure>Pharmacodynamic Endpoint: Change From Baseline in CD19+ B-cell Count During the Study Period</measure>
    <time_frame>Samples for pharmacodynamic evaluation (CD19+ B-cell) were taken at Baseline and Weeks 0, 1, 2, 3, 4, 8, 12, 16, 20 and 24. Unscheduled visit samples were taken at the discretion of the investigator.</time_frame>
    <description>Pharmacodynamic endpoint: Descriptive statistics (mean [SD]) of the change from baseline in CD19+ B-cell count during the study period (Day 15 [AUEC(0-d15] and Week 24 [AUEC(0-w24])</description>
  </other_outcome>
  <other_outcome>
    <measure>Pharmacodynamic Endpoint: Change From Baseline in C-reactive Protein (CRP) Levels at Weeks 8, 16, 24, 36 and 52</measure>
    <time_frame>Baseline (Day 1) and Weeks 8, 16, 24, 26 &amp; 52 (EOS)</time_frame>
    <description>Pharmacodynamic endpoint: Change from baseline (Day 1) in C-reactive protein (CRP) levels (mg/dL) at weeks 8, 16, 24, 36 and 52 (EOS)</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">294</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>SAIT101</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Part A, each patient will receive one course of two 1000 mg SAIT101 infusions: one on Day 1 and the second on Day 15. In Part B, patients with an inadequate response (&lt;50% improvement from Baseline in swollen and tender joint count at Week 24) will be eligible for a further course of two 1000 mg infusions of SAIT101 on Week 24 and Week 26.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rituxan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In Part A, each patient will receive one course of two 1000 mg Rituxan infusions: one on Day 1 and the second on Day 15. In Part B, patients with an inadequate response (&lt;50% improvement from Baseline in swollen and tender joint count at Week 24) will be randomised in a 1:1 ratio to receive Rituxan or SAIT101 10000 mg infusions on Week 24 and Week 26.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MabThera</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In Part A, each patient will receive one course of two 1000 mg MabThera infusions: one on Day 1 and the second on Day 15. In Part B, patients with an inadequate response (&lt;50% improvement from Baseline in swollen and tender joint count at Week 24) will be eligible for a further course of two 1000 mg infusions of MabThera on Week 24 and Week 26.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>SAIT101</intervention_name>
    <description>1,000 mg i.v. of SAIT101 on Day 1 and 15. 1,000 mg i.v. of SAIT101 on week 24 and 26 for eligible patients.</description>
    <arm_group_label>SAIT101</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MabThera</intervention_name>
    <description>1,000 mg i.v. of MabThera® on Day 1 and 15. 1,000 mg i.v. of MabThera® on week 24 and 26 for eligible patients.</description>
    <arm_group_label>MabThera</arm_group_label>
    <other_name>Rituximab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Rituxan</intervention_name>
    <description>1,000 mg i.v. of Rituxan® on Day 1 and 15. 1,000 mg i.v. of Rituxan® on week 24 and 26 for eligible patients.</description>
    <arm_group_label>Rituxan</arm_group_label>
    <other_name>Rituximab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1. Severe RA defined as:

          -  Diagnosis of RA according to the revised (1987) American College of Rheumatology (ACR)
             criteria for the classification of RA for at least 3 months prior to screening visit
             (see Appendix 3).

          -  And ≥6 swollen joints and ≥6 tender/painful joints (from the 66/68 joint count
             system).

          -  And C-reactive protein (CRP) ≥1.0 mg/dL or an erythrocyte sedimentation rate (ESR) ≥28
             mm/hour at Screening.

          -  And positive rheumatoid factor (RF) (≥20 units/mL) or anti cyclic citrullinase peptide
             (CCP) antibodies (≥10 units/mL) at Screening.

             2. Patients with severe RA who have had an inadequate response to at least 3 months'
             treatment (according to the approved treatment and dosage) or intolerance (at
             Investigator's discretion and/or experience of intolerable AE or toxicity such as
             infusion related reaction, hypersensitivity, anaphylaxis or severe toxicity) to
             anti-tumour necrosis factor (TNF) therapy (experience of severe adverse event (AE) or
             toxicity).

             3. Current treatment for RA on an outpatient basis:

          -  Receiving methotrexate (MTX) 7.5 - 25mg/week (oral or parenteral) for at least 12
             weeks, including the last 4 weeks prior to Day 1 at a stable dose, via the same route
             of administration, dose, and formulation. Patients receiving a lower dose of MTX (&lt;10
             mg/week), stable for 4 weeks prior to Day 1, should be doing so as a result of a
             documented evidence of intolerance to higher doses of MTX.

        Exclusion Criteria:

          1. Females who are pregnant, breastfeeding, or planning a pregnancy during the Treatment
             Period of and 12 months after the last infusion of study drug.

          2. Class IV as per the Classification of Global Functional Status in Rheumatoid Arthritis
             (as per ACR 1991 Revised Criteria) (see Appendix 4) or wheelchair/bed bound.

          3. History of or current inflammatory joint disease other than RA (including but not
             limited to gout, reactive arthritis, psoriatic arthritis, seronegative
             spondyloarthropathy or Lyme disease).

          4. History of or current systemic autoimmune disorder (including but not limited to
             systemic lupus erythematosus, inflammatory bowel disease, pulmonary fibrosis, Felty
             syndrome, scleroderma, inflammatory myopathy, fibromyalgia, juvenile idiopathic
             arthritis, mixed connective tissue disease, vasculitis or other overlap syndrome),
             with the exception of the secondary Sjögren's syndrome.

          5. Primary or secondary immunodeficiency (history of, or currently active), including
             known history of human immunodeficiency virus (HIV) infection or positive test at
             screening.

          6. History of opportunistic infection.

          7. History of deep space/tissue infection (e.g., fasciitis, abscess, osteomyelitis) and
             infected prosthetic joint.

          8. Active infection of any kind (excluding fungal infection of nail beds) or any major
             episode of infection requiring hospitalization or treatment with i.v. anti infective
             agents within 4 weeks prior to Screening or oral anti-infective agents within 2 weeks
             prior to Screening or use of antibiotic therapy three or more times in the last six
             months prior to Screening

          9. Positive serological test for hepatitis B surface antigen (HBsAg), hepatitis B core
             antibody (HBcAb) or hepatitis C serology.

               -  Patients with a negative HBsAg and positive HBcAb must have a hepatitis B virus
                  (HBV) deoxyribonucleic acid (DNA) level &lt;20 IU/mL (or 112 copies/mL) by
                  polymerase chain reaction (PCR). These HBV patients must be willing to undergo
                  monthly PCR HBV DNA testing during treatment and may participate following
                  consultation with a hepatitis expert regarding monitoring and use of HBV
                  antiviral therapy, and provided they agree to receive treatment as indicated. An
                  HBV re-test will be performed monthly including Day 1, Weeks 4, 8, 12, 16, 20,
                  24, 36, 52, and unscheduled visit if required.

               -  Patients with a positive test because of HBV vaccine may be included (i.e.,
                  anti-HBs+ and anti HBc-).

               -  Patients positive for hepatitis C virus (HCV) antibody are eligible only if PCR
                  is negative for HCV ribonucleic acid (RNA).

         10. Confirmed current active tuberculosis (TB). • Patients with latent TB as determined by
             positive QuantiFERON-TB test may be enrolled if such patients have written
             confirmation from health care provider (e.g., Pulmonologist or Infection Specialist)
             of adequate prophylaxis before or within the screening period and no evidence of
             tuberculosis on a chest X-ray performed within 3 months from Day 1.

             • Screening period can be extended to 60 days for prophylaxis of latent TB.

             • QuantiFERON-TB test can be re-tested, if inconclusive.

         11. Any significant cardiac disease (e.g., coronary artery disease with unstable angina,
             coronary heart failure New York Heart Association Class III and IV, familial long QT
             syndrome, uncontrolled cardiac disease).

         12. History of moderate to severe chronic obstructive pulmonary disease (COPD) and/or
             history of severe COPD exacerbation(s) within the last 12 months of Screening.

         13. Vaccination with live or attenuated vaccines within 6 weeks prior to first dose of
             study drug or planned administration during study participation or within 4 weeks
             following last dose of study drug. Treatment with IV Gamma Globulin or the Prosorba®
             Column within 6 months prior to Day 1.

         14. History of a severe allergic reaction or anaphylactic reaction to a biological agent
             or history of hypersensitivity to any component of the study drug including known
             hypersensitivity or allergy to a murine product.

         15. Hypogammaglobulinemia at screening (Immunoglobulin G (IgG) &lt;600 mg/dL).

         16. Patients with hemoglobin &lt;8.5 g/dL, absolute neutrophil count (ANC) &lt;1,500 cells/µL or
             platelet count &lt;75,000 cells/µL at Screening. If a patient has findings marginally
             below this limit, re testing is allowed, at the Investigator's discretion, within the
             30 day period between Visit 1 and Visit 2.

        • Creatinine clearance &lt; 50 mL/min (Cockcroft-Gault formula)

        • Liver function: Total bilirubin &gt;2.0 mg/dL (&gt;34 µmol/L) except for patients with
        Gilbert's Syndrome or hemolysis. Aspartate aminotransferase (AST) and alanine
        aminotransferase (ALT) &gt;3 × upper limit of normal (ULN). Patients with total bilirubin &gt;2.0
        mg/dL possibly due to Gilbert's Syndrome should have a direct bilirubin checked. If the
        direct bilirubin is normal and medical history is suggestive/positive for Gilbert's
        Syndrome, the patient successfully meets the criteria.

        The AST and ALT may be repeated once within the Screening period if the initial result
        exceeds this limit, and the lesser value accepted if it meets this criterion.

        18. History of cancer within the last 5 years prior to Screening, treated with anti-cancer
        chemotherapy, including solid tumors and hematologic malignancies and carcinoma in situ
        (except basal cell and squamous cell carcinomas of the skin or carcinoma in situ of the
        cervix uteri that have been excised and cured).

        19. Major surgical procedure within 4 weeks prior to or planned within 24 weeks of Day 1,
        with the exception of surgical procedures for dental prosthesis.

        20. Previous treatment with a B cell modulating or B cell depletion therapy, such as, but
        not limited to rituximab, belimumab, atacicept, tabalumab, ocrelizumab, ofatumumab,
        obinutuzumab, epratuzumab and other experimental treatments.

        21. Injectable corticosteroids within 6 weeks prior to Day 1.

        22. Participation in a previous clinical study within 4 weeks of Screening or having
        received treatment with a drug that has not received regulatory approval for any indication
        within a minimum of 5 half-lives prior to Day 1.

        23. Patients who, based on the Investigator's judgment, have a clinically significant or
        unstable medical or surgical condition that may preclude safe and complete study
        participation. Conditions may also include cardiovascular, vascular, pulmonary, hepatic,
        renal, endocrine or neurological conditions as determined by medical history, physical
        examination, laboratory tests or electrocardiogram (ECG).

        24. Patients who, in the judgment of the Investigator, are likely to be non-compliant or
        uncooperative during the study.

        25. History of substance abuse (alcohol or drug).

        26. History of demyelinating disorders (such as multiple sclerosis or Guillain-Barré
        syndrome).

        27. Patients at risk of progressive multifocal leukoencephalopathy (PML):

          -  Patients with immune deficiency such as transplant patients on immunosuppressive
             medications

          -  Patients receiving certain kinds of chemotherapy

          -  Patients receiving natalizumab (Tysabri®) for multiple sclerosis

          -  Patients with psoriasis on longer term efalizumab (Raptiva®) or patients with acquired
             immunodeficiency syndrome (AIDS)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Anniston</city>
        <state>Alabama</state>
        <zip>36207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>El Cajon</city>
        <state>California</state>
        <zip>92020</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>La Mesa</city>
        <state>California</state>
        <zip>91942</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lakewood</city>
        <state>California</state>
        <zip>90712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site-1</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site-2</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Leandro</city>
        <state>California</state>
        <zip>94578</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lansing</city>
        <state>Michigan</state>
        <zip>48917</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Waco</city>
        <state>Texas</state>
        <zip>76710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mostar</city>
        <zip>88000</zip>
        <country>Bosnia and Herzegovina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Sarajevo</city>
        <zip>71000</zip>
        <country>Bosnia and Herzegovina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site-1</name>
      <address>
        <city>Plovdiv</city>
        <zip>4002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site-2</name>
      <address>
        <city>Plovdiv</city>
        <zip>4002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sofia</city>
        <zip>1336</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sofia</city>
        <zip>1612</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Brno</city>
        <zip>656 91</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Ostrava</city>
        <zip>702 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Praha 2</city>
        <zip>128 50</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Uherské Hradiště</city>
        <zip>686 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Bad Doberan</city>
        <state>Mecklegurg-Vorpommern</state>
        <zip>18209</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Ratingen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>40882</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Vogelsang</city>
        <state>Sachsen-Anhalt</state>
        <zip>39245</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>01067</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Hamburg</city>
        <zip>22143</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Rendsburg</city>
        <zip>24768</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Budapest</city>
        <zip>1027</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Budapest</city>
        <zip>1083</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560054</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Hubli</city>
        <state>Karnataka</state>
        <zip>580021</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411005</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411007</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Bīkaner</city>
        <state>Rajasthan</state>
        <zip>334003</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Jaipur</city>
        <state>Rajasthan</state>
        <zip>302001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Kolkata</city>
        <state>West Bengal</state>
        <zip>700107</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Anyang</city>
        <zip>14068</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Busan</city>
        <zip>49201</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Busan</city>
        <zip>49241</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Daegu</city>
        <zip>41944</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Daegu</city>
        <zip>42472</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Daejeon</city>
        <zip>35015</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gwangju</city>
        <zip>61469</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jeju</city>
        <zip>63241</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>04763</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>07061</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Suwon</city>
        <zip>16247</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Durango</city>
        <zip>34000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mexico City</city>
        <zip>06700</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mexico City</city>
        <zip>07020</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Gdańsk</city>
        <zip>80-952</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Kraków</city>
        <zip>30-033</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Kraków</city>
        <zip>30-363</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Kłodzko</city>
        <zip>57-300</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Nowa Sól</city>
        <zip>67-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Oświęcim</city>
        <zip>32-600</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Poznań</city>
        <zip>60-773</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Poznań</city>
        <zip>61-113</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Tychy</city>
        <zip>43-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Warszawa</city>
        <zip>00-660</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Warszawa</city>
        <zip>03-291</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Wrocław</city>
        <zip>51-128</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Zamość</city>
        <zip>22-400</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fuenlabrada</city>
        <zip>28942</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>La Coruña</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>La Coruña</city>
        <zip>15702</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>La Coruña</city>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sevilla</city>
        <zip>41010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sevilla</city>
        <zip>41014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bosnia and Herzegovina</country>
    <country>Bulgaria</country>
    <country>Czechia</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>June 20, 2016</study_first_submitted>
  <study_first_submitted_qc>June 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2016</study_first_posted>
  <results_first_submitted>October 17, 2019</results_first_submitted>
  <results_first_submitted_qc>February 4, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">February 17, 2020</results_first_posted>
  <last_update_submitted>February 4, 2020</last_update_submitted>
  <last_update_submitted_qc>February 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>an inadequate response to anti -TNF therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 27, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/26/NCT02819726/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 13, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/26/NCT02819726/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This was a global study conducted in 66 study centres. The first participant entered the study on 11 October 2016 and the date of the last participants last study visit was 07 November 2018.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>SAIT101 (Part A and B)</title>
          <description>1000 mg intravenous (iv) SAIT101 on Day 1 and 15 (Part A). 1000 mg iv SAIT101 on week 24 and 26 (Part B) for eligible participants,</description>
        </group>
        <group group_id="P2">
          <title>MabThera (Part A and B)</title>
          <description>1000 mg iv MabThera on Day 1 and 15 (Part A). 1000 mg iv MabThera on week 24 and 26 (Part B) for eligible participants.</description>
        </group>
        <group group_id="P3">
          <title>Rituxan (Part A and B)</title>
          <description>1000 mg iv of Rituxan on Day 1 and 15 (Part A). 1000 mg iv of Rituxan on week 24 and 26 (Part B) for eligible participants</description>
        </group>
        <group group_id="P4">
          <title>SAIT101 (Part B Only)</title>
          <description>1000 mg iv SAIT101 on week 24 and 26 (Part B) for eligible participants,</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Part A (All Participants)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="98"/>
                <participants group_id="P2" count="98"/>
                <participants group_id="P3" count="98"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="92"/>
                <participants group_id="P2" count="88"/>
                <participants group_id="P3" count="87"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol non-compliance</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Part B (All Participants)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="73">19 participants who completed Part A were not eligible for Part B</participants>
                <participants group_id="P2" count="70">18 participants completing Part A were not eligible for Part B</participants>
                <participants group_id="P3" count="39">5 participants completing Part A were ineligible for Part B.</participants>
                <participants group_id="P4" count="38">5 participants completing Part A were ineligible for Part B.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="70"/>
                <participants group_id="P2" count="68"/>
                <participants group_id="P3" count="35"/>
                <participants group_id="P4" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol non-compliance</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>SAIT101</title>
          <description>SAIT101: 1,000 mg i.v. of SAIT101 on Day 1 and 15. 1,000 mg i.v. of SAIT101 on week 24 and 26 for eligible participants.</description>
        </group>
        <group group_id="B2">
          <title>MabThera</title>
          <description>MabThera: 1,000 mg i.v. of MabThera® on Day 1 and 15. 1,000 mg i.v. of MabThera® on week 24 and 26 for eligible participants.</description>
        </group>
        <group group_id="B3">
          <title>Rituxan</title>
          <description>Rituxan: 1,000 mg i.v. of Rituxan® on Day 1 and 15. 1,000 mg i.v. of Rituxan® on week 24 and 26 for eligible participants.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="98"/>
            <count group_id="B2" value="98"/>
            <count group_id="B3" value="98"/>
            <count group_id="B4" value="294"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="98"/>
                    <count group_id="B2" value="98"/>
                    <count group_id="B3" value="98"/>
                    <count group_id="B4" value="294"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.9" spread="12.41"/>
                    <measurement group_id="B2" value="52.5" spread="10.87"/>
                    <measurement group_id="B3" value="52.1" spread="12.09"/>
                    <measurement group_id="B4" value="51.8" spread="11.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>18-60 years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="98"/>
                    <count group_id="B2" value="98"/>
                    <count group_id="B3" value="98"/>
                    <count group_id="B4" value="294"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                    <measurement group_id="B2" value="75"/>
                    <measurement group_id="B3" value="71"/>
                    <measurement group_id="B4" value="222"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;60 years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="98"/>
                    <count group_id="B2" value="98"/>
                    <count group_id="B3" value="98"/>
                    <count group_id="B4" value="294"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="98"/>
                    <count group_id="B2" value="98"/>
                    <count group_id="B3" value="98"/>
                    <count group_id="B4" value="294"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="79"/>
                    <measurement group_id="B2" value="81"/>
                    <measurement group_id="B3" value="80"/>
                    <measurement group_id="B4" value="240"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="98"/>
                    <count group_id="B2" value="98"/>
                    <count group_id="B3" value="98"/>
                    <count group_id="B4" value="294"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="29"/>
                    <measurement group_id="B4" value="89"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="68"/>
                    <measurement group_id="B2" value="68"/>
                    <measurement group_id="B3" value="69"/>
                    <measurement group_id="B4" value="205"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="98"/>
                    <count group_id="B2" value="98"/>
                    <count group_id="B3" value="98"/>
                    <count group_id="B4" value="294"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="65"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="61"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="52"/>
                    <measurement group_id="B4" value="160"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>South Korea</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="98"/>
                    <count group_id="B2" value="98"/>
                    <count group_id="B3" value="98"/>
                    <count group_id="B4" value="294"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hungary</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="98"/>
                    <count group_id="B2" value="98"/>
                    <count group_id="B3" value="98"/>
                    <count group_id="B4" value="294"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Czechia</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="98"/>
                    <count group_id="B2" value="98"/>
                    <count group_id="B3" value="98"/>
                    <count group_id="B4" value="294"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="98"/>
                    <count group_id="B2" value="98"/>
                    <count group_id="B3" value="98"/>
                    <count group_id="B4" value="294"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="98"/>
                    <count group_id="B2" value="98"/>
                    <count group_id="B3" value="98"/>
                    <count group_id="B4" value="294"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mexico</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="98"/>
                    <count group_id="B2" value="98"/>
                    <count group_id="B3" value="98"/>
                    <count group_id="B4" value="294"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bulgaria</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="98"/>
                    <count group_id="B2" value="98"/>
                    <count group_id="B3" value="98"/>
                    <count group_id="B4" value="294"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bosnia and Herzegovina</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="98"/>
                    <count group_id="B2" value="98"/>
                    <count group_id="B3" value="98"/>
                    <count group_id="B4" value="294"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="98"/>
                    <count group_id="B2" value="98"/>
                    <count group_id="B3" value="98"/>
                    <count group_id="B4" value="294"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>India</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="98"/>
                    <count group_id="B2" value="98"/>
                    <count group_id="B3" value="98"/>
                    <count group_id="B4" value="294"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="98"/>
                    <count group_id="B2" value="98"/>
                    <count group_id="B3" value="98"/>
                    <count group_id="B4" value="294"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Disease duration</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="98"/>
                    <count group_id="B2" value="98"/>
                    <count group_id="B3" value="98"/>
                    <count group_id="B4" value="294"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.8" spread="6.73"/>
                    <measurement group_id="B2" value="11.2" spread="7.72"/>
                    <measurement group_id="B3" value="9.3" spread="7.10"/>
                    <measurement group_id="B4" value="10.1" spread="7.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>C-reactive protein</title>
          <description>C-reactive protein (CRP) level (Mg/L). CRP is a marker for inflammation. a normal reading is &lt;3 Mg/L. Higher values indicate disease related inflammation and increased cardiovascular risk.
CRP levels between 3 Mg/L and 10 Mg/L are mildly elevated. Levels between 10 Mg/L and 100 Mg/L are moderately elevated and CRP levels above 100 Mg/L are severely elevated.</description>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="98"/>
                    <count group_id="B2" value="98"/>
                    <count group_id="B3" value="98"/>
                    <count group_id="B4" value="294"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19.5" spread="28.99"/>
                    <measurement group_id="B2" value="15.3" spread="20.63"/>
                    <measurement group_id="B3" value="16.2" spread="17.91"/>
                    <measurement group_id="B4" value="17.0" spread="2.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Erythrocyte sedimentation rate</title>
          <population>Results were not available for 1 participant in each treatment arm</population>
          <units>mm/hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="97"/>
                    <count group_id="B2" value="97"/>
                    <count group_id="B3" value="97"/>
                    <count group_id="B4" value="291"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.0" spread="26.58"/>
                    <measurement group_id="B2" value="47.5" spread="22.87"/>
                    <measurement group_id="B3" value="51.5" spread="23.35"/>
                    <measurement group_id="B4" value="50.0" spread="24.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Swollen Joint Count (SJC66)</title>
          <population>Results were not available for 1 participant in the MabThera treatment arm</population>
          <units>Joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="98"/>
                    <count group_id="B2" value="97"/>
                    <count group_id="B3" value="98"/>
                    <count group_id="B4" value="293"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15.2" spread="7.97"/>
                    <measurement group_id="B2" value="15.2" spread="7.01"/>
                    <measurement group_id="B3" value="13.0" spread="6.19"/>
                    <measurement group_id="B4" value="14.5" spread="7.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Tender Joint Count (TJC68)</title>
          <population>Results were not available for 1 participant in the MabThera treatment arm</population>
          <units>Joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="98"/>
                    <count group_id="B2" value="97"/>
                    <count group_id="B3" value="98"/>
                    <count group_id="B4" value="293"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21.7" spread="11.08"/>
                    <measurement group_id="B2" value="22.6" spread="13.66"/>
                    <measurement group_id="B3" value="20.0" spread="10.84"/>
                    <measurement group_id="B4" value="21.4" spread="11.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Patient Global Assessments Visual Analogue Scale (VAS) Score</title>
          <description>Patients global assessment of disease activity (assessed on 1 to 100 mm Visual Analog Scale [VAS]). Where 0 = no disease activity and 100 = maximum disease activity.</description>
          <population>Results were not available for 1 participant in each treatment arm</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="97"/>
                    <count group_id="B2" value="97"/>
                    <count group_id="B3" value="97"/>
                    <count group_id="B4" value="291"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68.9" spread="15.87"/>
                    <measurement group_id="B2" value="67.6" spread="17.53"/>
                    <measurement group_id="B3" value="70.8" spread="17.04"/>
                    <measurement group_id="B4" value="69.1" spread="16.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Physician Global Assessment VAS Score</title>
          <description>Physicians global assessment of disease activity (assessed on 1 to 100 mm Visual Analog Scale [VAS]). Where 0 = no disease activity and 100 = maximum disease activity.</description>
          <population>Results were not available for 1 participant in the SAIT101 treatment arm and 1 participant in the MabThera treatment arm</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="97"/>
                    <count group_id="B2" value="97"/>
                    <count group_id="B3" value="98"/>
                    <count group_id="B4" value="292"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71.0" spread="14.3"/>
                    <measurement group_id="B2" value="69.4" spread="15.9"/>
                    <measurement group_id="B3" value="69.8" spread="14.32"/>
                    <measurement group_id="B4" value="70.1" spread="14.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Patient Pain Assessment VAS Score</title>
          <description>Patients assessment of pain (assessed on 1 to 100 mm Visual Analog Scale [VAS]) where 0 = no pain and 100 = severe pain.</description>
          <population>Results were not available for 1 participant in the Rituxan treatment arm</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="98"/>
                    <count group_id="B2" value="98"/>
                    <count group_id="B3" value="97"/>
                    <count group_id="B4" value="293"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.0" spread="18.71"/>
                    <measurement group_id="B2" value="68.8" spread="20.02"/>
                    <measurement group_id="B3" value="70.7" spread="19.06"/>
                    <measurement group_id="B4" value="68.8" spread="19.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Health Assessment Questionnaire Disability Index (HAQ-DI) Score</title>
          <description>HAQ-DI contains 20 questions split into 8 categories (dressing &amp; grooming, arising, eating, walking, hygiene, reach, grip &amp; activities).
Scores were: 0 = Without ANY Difficulty; 1 = With SOME Difficulty; 2 = With MUCH Difficulty; 3 = UNABLE to Do. Total scores were calculated as the summed category scores divided by the number of categories.
Total HAQ-DI scores are presented which range from 0 to 3. Higher scores represent a worse outcome. Scores of 0 to 1 represent mild to moderate difficulty, 1 to 2 moderate disability, and 2 to 3 severe to very severe disability.</description>
          <population>Results were not available for 1 participant in the Rituxan treatment arm</population>
          <units>Score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="98"/>
                    <count group_id="B2" value="98"/>
                    <count group_id="B3" value="97"/>
                    <count group_id="B4" value="293"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.7" spread="0.57"/>
                    <measurement group_id="B2" value="1.7" spread="0.64"/>
                    <measurement group_id="B3" value="1.6" spread="0.64"/>
                    <measurement group_id="B4" value="1.7" spread="0.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Disease activity score based on a 28-joint count-C-Reactive Protein (DAS-28-CRP(</title>
          <description>Disease Activity Score 28-C-Reactive Protein (DAS28-CRP) consisted of tender joint counts (TJC), swollen joint counts (SJC) &amp; C-reactive protein (CRP) blood levels. Total DAS28-CRPscores are presented and range from 2.0 (minimum) to 10 (maximum). Lower scores represent a better patient outcome. Disease remission is considered achieved if the score is between 0 and &lt;2.6. Low disease activity corresponds to 2.6 to &lt;3.2. Moderate activity is between 3.2 &amp; ≤5.1, while high activity is above 5.1.</description>
          <population>Results were not available for 1 participant in the MabThera treatment arm</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="98"/>
                    <count group_id="B2" value="97"/>
                    <count group_id="B3" value="98"/>
                    <count group_id="B4" value="293"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.28" spread="0.890"/>
                    <measurement group_id="B2" value="5.29" spread="0.807"/>
                    <measurement group_id="B3" value="5.17" spread="0833"/>
                    <measurement group_id="B4" value="5.25" spread="0.843"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Disease activity score based on a 28-joint count - Erythrocyte sedimentation Rate (DAS28-ESR)</title>
          <description>Disease Activity Score 28- Erythrocyte Sedimentation Rate (DAS28-ESR) consisted of tender joint counts (TJC), swollen joint counts (SJC) &amp; erythrocyte sedimentation rate (ESR). The formula is: [0.56*SQRT(tender 28 joint count)+0.28*SQRT(swollen 28 joint count)+0.7*ln(ESR)]+0.014*patient global health assessment.
Total DAS28-ESR scores are presented. Total scores range from 2 (minimum) to 10 (maximum). A lower score represented a better patient outcome. A DAS28-ESR of greater than 5.1 implies active disease, less than 3.2 low disease activity, and less than 2.6 remission.
.</description>
          <population>Results were not available for 2 participants in each treatment arm</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="96"/>
                    <count group_id="B2" value="96"/>
                    <count group_id="B3" value="96"/>
                    <count group_id="B4" value="288"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.54" spread="0.844"/>
                    <measurement group_id="B2" value="6.53" spread="0.781"/>
                    <measurement group_id="B3" value="6.48" spread="0.758"/>
                    <measurement group_id="B4" value="6.52" spread="0.793"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Anti-drug Antibody (ADA) Status Positive</title>
          <population>Results were not available for 2 participants in the Rituxan arm</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="98"/>
                    <count group_id="B2" value="98"/>
                    <count group_id="B3" value="96"/>
                    <count group_id="B4" value="292"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <population>Results were not available for 1 participant in the Rituxan treatment arm</population>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="98"/>
                    <count group_id="B2" value="98"/>
                    <count group_id="B3" value="97"/>
                    <count group_id="B4" value="293"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="162.6" spread="9.29"/>
                    <measurement group_id="B2" value="161.3" spread="8.79"/>
                    <measurement group_id="B3" value="163.3" spread="8.37"/>
                    <measurement group_id="B4" value="162.4" spread="8.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="98"/>
                    <count group_id="B2" value="98"/>
                    <count group_id="B3" value="98"/>
                    <count group_id="B4" value="294"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73.0" spread="17.62"/>
                    <measurement group_id="B2" value="71.9" spread="16.94"/>
                    <measurement group_id="B3" value="71.6" spread="17.99"/>
                    <measurement group_id="B4" value="72.2" spread="17.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <population>Results were not available for 1 participant in the Rituxan treatment arm</population>
          <units>Kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="98"/>
                    <count group_id="B2" value="98"/>
                    <count group_id="B3" value="97"/>
                    <count group_id="B4" value="293"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.5" spread="5.48"/>
                    <measurement group_id="B2" value="27.5" spread="5.46"/>
                    <measurement group_id="B3" value="26.7" spread="5.95"/>
                    <measurement group_id="B4" value="27.2" spread="5.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Concentration Time Cure From Time 0 to Last Quantifiable Concentration (AUC0-t)</title>
        <description>Pharmacokinetic endpoint: Area under the concentration-time curve from time 0 (immediately predose on Day 1) to last quantifiable concentration (AUC0-t). Geometric means by treatment (Pharmacokinetic Analysis Set).</description>
        <time_frame>Samples for pharmacokinetic evaluation were taken at Baseline and Weeks 0, 1, 2, 3, 4, 8, 12, 16, 20 and 24. Unscheduled visit samples were taken at the discretion of the investigator.</time_frame>
        <population>Pharmacokinetic Analysis Set. (AUC(0-t) could not be determined for 15 participants in the SAIT101 arm, 23 participants in the MabThera arm and 17 in the Rituxan arm as the Week 24 sample was either collected post-dose (i.e. not evaluable), was out of the collection window or was missing.</population>
        <group_list>
          <group group_id="O1">
            <title>SAIT101</title>
            <description>1000 mg intravenous (iv) SAIT101 on Day 1 and 15 (Part A). 1000 mg iv SAIT101 on week 24 and 26 (Part B) for eligible participants,</description>
          </group>
          <group group_id="O2">
            <title>MabThera</title>
            <description>1000 mg iv MabThera on Day 1 and 15 (Part A). 1000 mg iv MabThera on week 24 and 26 (Part B) for eligible participants.</description>
          </group>
          <group group_id="O3">
            <title>Rituxan</title>
            <description>1000 mg iv of Rituxan on Day 1 and 15 (Part A). 1000 mg iv of Rituxan on week 24 and 26 (Part B) for eligible participants</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration Time Cure From Time 0 to Last Quantifiable Concentration (AUC0-t)</title>
          <description>Pharmacokinetic endpoint: Area under the concentration-time curve from time 0 (immediately predose on Day 1) to last quantifiable concentration (AUC0-t). Geometric means by treatment (Pharmacokinetic Analysis Set).</description>
          <population>Pharmacokinetic Analysis Set. (AUC(0-t) could not be determined for 15 participants in the SAIT101 arm, 23 participants in the MabThera arm and 17 in the Rituxan arm as the Week 24 sample was either collected post-dose (i.e. not evaluable), was out of the collection window or was missing.</population>
          <units>h*µg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="70"/>
                <count group_id="O3" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="144500" spread="34.2"/>
                    <measurement group_id="O2" value="151600" spread="33.2"/>
                    <measurement group_id="O3" value="154600" spread="35.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The statistical comparison of the loge-transformed primary parameters between treatments is based on an analysis of variance model (ANOVA) with fixed effect for treatment</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Standard acceptance limits for bioequivalence (80.00% to 125.00%) for all treatment comparisons</non_inferiority_desc>
            <param_type>GLS Mean Ration</param_type>
            <param_value>95.33</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>87.07</ci_lower_limit>
            <ci_upper_limit>104.37</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The statistical comparison of the loge-transformed primary parameters between treatments is based on an analysis of variance (ANOVA) model with fixed effect for treatment</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Standard acceptance limits for bioequivalence (80.00% to 125.00%) for all treatment comparisons</non_inferiority_desc>
            <param_type>GLS Mean Ratio</param_type>
            <param_value>93.43</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>85.54</ci_lower_limit>
            <ci_upper_limit>102.15</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The statistical comparison of the loge-transformed primary parameters between treatments is based on an analysis of variance model (ANOVA) with fixed effect for treatment</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Standard acceptance limits for bioequivalence (80.00% to 125.00%) for all treatment comparisons</non_inferiority_desc>
            <param_type>GLS Mean Ratio</param_type>
            <param_value>98.06</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>89.49</ci_lower_limit>
            <ci_upper_limit>107.45</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma Concentration Versus Time Curve (AUC0-∞)</title>
        <description>Pharmacokinetic endpoint: Area Under the Plasma Concentration from time 0 to infinity (AUC0-∞ (infinity). Calculated by linear up/log down trapezoidal summation and extrapolated to infinity by addition of the last quantifiable concentration divided by the elimination rate constant: AUC(0-last) + C(last)/λz.</description>
        <time_frame>Samples for pharmacokinetic evaluation were taken at Baseline and Weeks 0, 1, 2, 3, 4, 8, 12, 16, 20 and 24. Unscheduled visit samples were taken at the discretion of the investigator.</time_frame>
        <population>Pharmacokinetic Analysis Set. AUC0-∞ could not be calculated for 1 participant in the SAIT101 arm, 2 participants in the MabThera arm and 2 participants in the Rituxan arm as either the terminal phase was undetermined, the samples were missing or the Regulatory Scientific Quality (RSQ) was &lt;0.800.</population>
        <group_list>
          <group group_id="O1">
            <title>SAIT101</title>
            <description>1000 mg intravenous (iv) SAIT101 on Day 1 and 15 (Part A). 1000 mg iv SAIT101 on week 24 and 26 (Part B) for eligible participants,</description>
          </group>
          <group group_id="O2">
            <title>MabThera</title>
            <description>1000 mg iv MabThera on Day 1 and 15 (Part A). 1000 mg iv MabThera on week 24 and 26 (Part B) for eligible participants.</description>
          </group>
          <group group_id="O3">
            <title>Rituxan</title>
            <description>1000 mg iv of Rituxan on Day 1 and 15 (Part A). 1000 mg iv of Rituxan on week 24 and 26 (Part B) for eligible participants</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration Versus Time Curve (AUC0-∞)</title>
          <description>Pharmacokinetic endpoint: Area Under the Plasma Concentration from time 0 to infinity (AUC0-∞ (infinity). Calculated by linear up/log down trapezoidal summation and extrapolated to infinity by addition of the last quantifiable concentration divided by the elimination rate constant: AUC(0-last) + C(last)/λz.</description>
          <population>Pharmacokinetic Analysis Set. AUC0-∞ could not be calculated for 1 participant in the SAIT101 arm, 2 participants in the MabThera arm and 2 participants in the Rituxan arm as either the terminal phase was undetermined, the samples were missing or the Regulatory Scientific Quality (RSQ) was &lt;0.800.</population>
          <units>h*µg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="93"/>
                <count group_id="O2" value="91"/>
                <count group_id="O3" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="152300" spread="34.6"/>
                    <measurement group_id="O2" value="161900" spread="32.2"/>
                    <measurement group_id="O3" value="161300" spread="33.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The statistical comparison of the loge-transformed primary parameters between treatments is based on an analysis of variance (ANOVA) model with fixed effect for treatment</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Standard acceptance limits for bioequivalence (80.00% to 125.00%) for all treatment comparisons</non_inferiority_desc>
            <param_type>GLS Mean Ratio</param_type>
            <param_value>94.07</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>86.91</ci_lower_limit>
            <ci_upper_limit>101.81</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The statistical comparison of the loge-transformed primary parameters between treatments is based on an analysis of variance (ANOVA) model with fixed effect for treatment</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Standard acceptance limits for bioequivalence (80.00% to 125.00%) for all treatment comparisons</non_inferiority_desc>
            <param_type>GLS Mean Ration</param_type>
            <param_value>94.39</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>87.21</ci_lower_limit>
            <ci_upper_limit>102.16</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The statistical comparison of the loge-transformed primary parameters between treatments is based on an analysis of variance (ANOVA) model with fixed effect for treatment</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Standard acceptance limits for bioequivalence (80.00% to 125.00%) for all treatment comparisons</non_inferiority_desc>
            <param_type>GLS Mean Ratio</param_type>
            <param_value>100.35</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>92.68</ci_lower_limit>
            <ci_upper_limit>108.65</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma Concentration Versus Time Curve (AUC0-D15)</title>
        <description>Pharmacokinetic endpoint: Area Under the Concentration verses time from time 0 to Day 15 prior to infusion (AUC0-D15) calculated by linear up/log down trapezoidal summation. Actual time/concentration on Day 15 was used for the calculation of this parameter unless the parameter was derived by interpolation.</description>
        <time_frame>Samples for pharmacokinetic evaluation were taken at Baseline and Weeks 0, 1, 2, 3, 4, 8, 12, 16, 20 and 24. Unscheduled visit samples were taken at the discretion of the investigator.</time_frame>
        <population>Pharmacokinetic Analysis Set. AUC0-D15 could not be determined for 3 participants in the SAIT101 arm, 5 participants in the MabThera arm and 10 participants in the Rituxan arm as either the 336-hours blood sample was collected &lt;312 hours or samples were missing.</population>
        <group_list>
          <group group_id="O1">
            <title>SAIT101</title>
            <description>1000 mg intravenous (iv) SAIT101 on Day 1 and 15 (Part A). 1000 mg iv SAIT101 on week 24 and 26 (Part B) for eligible participants,</description>
          </group>
          <group group_id="O2">
            <title>MabThera</title>
            <description>1000 mg iv MabThera on Day 1 and 15 (Part A). 1000 mg iv MabThera on week 24 and 26 (Part B) for eligible participants.</description>
          </group>
          <group group_id="O3">
            <title>Rituxan</title>
            <description>1000 mg iv of Rituxan on Day 1 and 15 (Part A). 1000 mg iv of Rituxan on week 24 and 26 (Part B) for eligible participants</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration Versus Time Curve (AUC0-D15)</title>
          <description>Pharmacokinetic endpoint: Area Under the Concentration verses time from time 0 to Day 15 prior to infusion (AUC0-D15) calculated by linear up/log down trapezoidal summation. Actual time/concentration on Day 15 was used for the calculation of this parameter unless the parameter was derived by interpolation.</description>
          <population>Pharmacokinetic Analysis Set. AUC0-D15 could not be determined for 3 participants in the SAIT101 arm, 5 participants in the MabThera arm and 10 participants in the Rituxan arm as either the 336-hours blood sample was collected &lt;312 hours or samples were missing.</population>
          <units>h*µg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42950" spread="26.7"/>
                    <measurement group_id="O2" value="44600" spread="25.6"/>
                    <measurement group_id="O3" value="43540" spread="24.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The statistical comparison of the loge-transformed primary parameters between treatments is based on an analysis of variance (ANOVA) model with fixed effect for treatment</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Standard acceptance limits for bioequivalence (80.00% to 125.00%) for all treatment comparisons</non_inferiority_desc>
            <param_type>GLS Mean Ratio</param_type>
            <param_value>96.31</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>90.52</ci_lower_limit>
            <ci_upper_limit>102.46</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The statistical comparison of the loge-transformed primary parameters between treatments is based on an analysis of variance (ANOVA) model with fixed effect for treatment</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Standard acceptance limits for bioequivalence (80.00% to 125.00%) for all treatment comparisons</non_inferiority_desc>
            <param_type>GLS Mean Ratio</param_type>
            <param_value>98.65</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>92.64</ci_lower_limit>
            <ci_upper_limit>105.05</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The statistical comparison of the loge-transformed primary parameters between treatments is based on an analysis of variance (ANOVA) model with fixed effect for treatment</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Standard acceptance limits for bioequivalence (80.00% to 125.00%) for all treatment comparisons</non_inferiority_desc>
            <param_type>GLS Mean Ratio</param_type>
            <param_value>102.43</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>96.14</ci_lower_limit>
            <ci_upper_limit>109.14</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Peak Plasma Concentration (Cmax) After Day 15 Infusion</title>
        <description>Pharmacokinetic endpoint: Maximum Plasma Concentration (Cmax) after Day 15 infusion (Dose 2)</description>
        <time_frame>Samples for pharmacokinetic evaluation were taken at Baseline and Weeks 0, 1 and 2 (Pre-dose 2). Unscheduled visit samples were taken at the discretion of the investigator.</time_frame>
        <population>Pharmacokinetic Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>SAIT101</title>
            <description>1000 mg intravenous (iv) SAIT101 on Day 1 and 15 (Part A). 1000 mg iv SAIT101 on week 24 and 26 (Part B) for eligible participants,</description>
          </group>
          <group group_id="O2">
            <title>MabThera</title>
            <description>1000 mg iv MabThera on Day 1 and 15 (Part A). 1000 mg iv MabThera on week 24 and 26 (Part B) for eligible participants.</description>
          </group>
          <group group_id="O3">
            <title>Rituxan</title>
            <description>1000 mg iv of Rituxan on Day 1 and 15 (Part A). 1000 mg iv of Rituxan on week 24 and 26 (Part B) for eligible participants</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Plasma Concentration (Cmax) After Day 15 Infusion</title>
          <description>Pharmacokinetic endpoint: Maximum Plasma Concentration (Cmax) after Day 15 infusion (Dose 2)</description>
          <population>Pharmacokinetic Analysis Set.</population>
          <units>µg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
                <count group_id="O2" value="93"/>
                <count group_id="O3" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="406.0" spread="28.3"/>
                    <measurement group_id="O2" value="427.7" spread="28.3"/>
                    <measurement group_id="O3" value="411.1" spread="24.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The statistical comparison of the loge-transformed primary parameters between treatments is based on an analysis of variance (ANOVA) model with fixed effect for treatment</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Standard acceptance limits for bioequivalence (80.00% to 125.00%) for all treatment comparisons</non_inferiority_desc>
            <param_type>GLS Mean Ratio</param_type>
            <param_value>94.93</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>89.03</ci_lower_limit>
            <ci_upper_limit>101.23</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The statistical comparison of the loge-transformed primary parameters between treatments is based on an analysis of variance (ANOVA) model with fixed effect for treatment</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Standard acceptance limits for bioequivalence (80.00% to 125.00%) for all treatment comparisons</non_inferiority_desc>
            <param_type>GLS Mean Ratio</param_type>
            <param_value>98.75</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>92.61</ci_lower_limit>
            <ci_upper_limit>105.30</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The statistical comparison of the loge-transformed primary parameters between treatments is based on an analysis of variance (ANOVA) model with fixed effect for treatment</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Standard acceptance limits for bioequivalence (80.00% to 125.00%) for all treatment comparisons</non_inferiority_desc>
            <param_type>GLS Mean Ratio</param_type>
            <param_value>104.03</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>97.54</ci_lower_limit>
            <ci_upper_limit>110.95</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Trough Concentration (Ctrough) Before the Second Infusion on Day 15</title>
        <description>Pharmacokinetic endpoint: Trough concentration (Ctrough) before the second infusion on Day 15 (Dose 2). Trough (pre-dose) concentration prior to second infusion on Day 15 obtained directly from the observed concentration versus time data.</description>
        <time_frame>Samples for pharmacokinetic evaluation were taken at Baseline and Weeks 0, 1 and 2 (Pre-dose 2). Unscheduled visit samples were taken at the discretion of the investigator.</time_frame>
        <population>Pharmacokinetic Analysis Set. Ctrough could not be determined for 11 participants in the SAIT101 arm, 12 participants in the MabThera arm and 16 participants in the Rituxan arm as samples were collected outside of a 312 to 360 hour window.</population>
        <group_list>
          <group group_id="O1">
            <title>SAIT101</title>
            <description>1000 mg intravenous (iv) SAIT101 on Day 1 and 15 (Part A). 1000 mg iv SAIT101 on week 24 and 26 (Part B) for eligible participants,</description>
          </group>
          <group group_id="O2">
            <title>MabThera</title>
            <description>1000 mg iv MabThera on Day 1 and 15 (Part A). 1000 mg iv MabThera on week 24 and 26 (Part B) for eligible participants.</description>
          </group>
          <group group_id="O3">
            <title>Rituxan</title>
            <description>1000 mg iv of Rituxan on Day 1 and 15 (Part A). 1000 mg iv of Rituxan on week 24 and 26 (Part B) for eligible participants</description>
          </group>
        </group_list>
        <measure>
          <title>Trough Concentration (Ctrough) Before the Second Infusion on Day 15</title>
          <description>Pharmacokinetic endpoint: Trough concentration (Ctrough) before the second infusion on Day 15 (Dose 2). Trough (pre-dose) concentration prior to second infusion on Day 15 obtained directly from the observed concentration versus time data.</description>
          <population>Pharmacokinetic Analysis Set. Ctrough could not be determined for 11 participants in the SAIT101 arm, 12 participants in the MabThera arm and 16 participants in the Rituxan arm as samples were collected outside of a 312 to 360 hour window.</population>
          <units>µg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="81"/>
                <count group_id="O3" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.35" spread="40.3"/>
                    <measurement group_id="O2" value="67.75" spread="36.2"/>
                    <measurement group_id="O3" value="58.84" spread="97.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The statistical comparison of the loge-transformed primary parameters between treatments is based on an analysis of variance (ANOVA) model with fixed effect for treatment</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Standard acceptance limits for bioequivalence (80.00% to 125.00%) for all treatment comparisons</non_inferiority_desc>
            <param_type>GLS Mean Ratio</param_type>
            <param_value>89.08</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>77.20</ci_lower_limit>
            <ci_upper_limit>102.79</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The statistical comparison of the loge-transformed primary parameters between treatments is based on an analysis of variance (ANOVA) model with fixed effect for treatment</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Standard acceptance limits for bioequivalence (80.00% to 125.00%) for all treatment comparisons</non_inferiority_desc>
            <param_type>GLS Mean Ratio</param_type>
            <param_value>102.56</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>88.72</ci_lower_limit>
            <ci_upper_limit>118.56</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The statistical comparison of the loge-transformed primary parameters between treatments is based on an analysis of variance (ANOVA) model with fixed effect for treatment</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Standard acceptance limits for bioequivalence (80.00% to 125.00%) for all treatment comparisons</non_inferiority_desc>
            <param_type>GLS Mean Ratio</param_type>
            <param_value>115.13</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>99.51</ci_lower_limit>
            <ci_upper_limit>133.21</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in DAS28-CRP at Week 24</title>
        <description>Disease Activity Score 28 C-reactive protein score (DAS28-CRP) at Week 24 (Full Analysis Set). CRP samples were collected at Baseline and Weeks 8, 16 and 24. DAS28-CRP was calculated using the following equation: [0.56*Square Root (SQRT) (tender 28 joint count)+0.28*SQRT(swollen 28 joint count)+0.36*ln(CRP+1)]*1.10+1.15.
Total DAS28-CRP scores were calculates and range from 2.0 (minimum) to 10 (maximum). Lower scores represent a better patient outcome. Disease remission is considered achieved if the score is between 0 and &lt;2.6. Low disease activity corresponds to 2.6 to &lt;3.2. Moderate activity is between 3.2 &amp; ≤5.1, while high activity is above 5.1.</description>
        <time_frame>Baseline and Week 24</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>SAIT101</title>
            <description>1000 mg intravenous (iv) SAIT101 on Day 1 and 15 (Part A). 1000 mg iv SAIT101 on week 24 and 26 (Part B) for eligible participants,</description>
          </group>
          <group group_id="O2">
            <title>MabThera</title>
            <description>1000 mg iv MabThera on Day 1 and 15 (Part A). 1000 mg iv MabThera on week 24 and 26 (Part B) for eligible participants.</description>
          </group>
          <group group_id="O3">
            <title>Rituxan</title>
            <description>1000 mg iv of Rituxan on Day 1 and 15 (Part A). 1000 mg iv of Rituxan on week 24 and 26 (Part B) for eligible participants</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in DAS28-CRP at Week 24</title>
          <description>Disease Activity Score 28 C-reactive protein score (DAS28-CRP) at Week 24 (Full Analysis Set). CRP samples were collected at Baseline and Weeks 8, 16 and 24. DAS28-CRP was calculated using the following equation: [0.56*Square Root (SQRT) (tender 28 joint count)+0.28*SQRT(swollen 28 joint count)+0.36*ln(CRP+1)]*1.10+1.15.
Total DAS28-CRP scores were calculates and range from 2.0 (minimum) to 10 (maximum). Lower scores represent a better patient outcome. Disease remission is considered achieved if the score is between 0 and &lt;2.6. Low disease activity corresponds to 2.6 to &lt;3.2. Moderate activity is between 3.2 &amp; ≤5.1, while high activity is above 5.1.</description>
          <population>Full Analysis Set</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="87"/>
                <count group_id="O3" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.991" spread="1.1735"/>
                    <measurement group_id="O2" value="-0.832" spread="0.8483"/>
                    <measurement group_id="O3" value="-0.861" spread="0.9488"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Least square means and confidence intervals (CIs) were estimated from an ANCOVA model containing treatment group as a factor and baseline DAS28-CRP value as a covariate. ANCOVA model contains treatment group only</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>The equivalence between 2 study treatments would be declared if the two-sided 95% CI of the difference in change from baseline in DAS28-CRP at week 24 in entirely contained within the equivalence margin of [-0.6,0.6]</non_inferiority_desc>
            <p_value>0.2402</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.16</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.134</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.422</ci_lower_limit>
            <ci_upper_limit>0.106</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Least square means and CIs were estimated from an ANCOVA model containing treatment group as a factor and baseline DAS28-CRP value as a covariate. ANCOVA model contains treatment group only</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>The equivalence between 2 study treatments would be declared if the two-sided 95% CI of the difference in change from baseline in DAS28-CRP at week 24 in entirely contained within the equivalence margin of [-0.6,0.6]</non_inferiority_desc>
            <p_value>0.1346</p_value>
            <method>ANCOVA</method>
            <param_type>LS Means Difference</param_type>
            <param_value>-0.20</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.135</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.469</ci_lower_limit>
            <ci_upper_limit>0.063</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Least square means and CIs were estimated from an ANCOVA model containing treatment group as a factor and baseline DAS28-CRP value as a covariate. ANCOVA model contains treatment group only</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>The equivalence between 2 study treatments would be declared if the two-sided 95% CI of the difference in change from baseline in DAS28-CRP at week 24 in entirely contained within the equivalence margin of [-0.6,0.6]</non_inferiority_desc>
            <p_value>0.7429</p_value>
            <method>ANCOVA</method>
            <param_type>LS Means Difference</param_type>
            <param_value>-0.04</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.137</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.314</ci_lower_limit>
            <ci_upper_limit>0.224</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Concentration Time Curve Week 2 to Week 24 (AUC(w2-24)</title>
        <description>Pharmacokinetic endpoint: Area under the concentration time curve week 2 to week 24 (AUC(w2-24) calculated by linear up/log down trapezoidal summation.</description>
        <time_frame>Samples for pharmacokinetic evaluation were taken at Baseline and Weeks 0, 1, 2, 3, 4, 8, 12, 16, 20 and 24. Unscheduled visit samples were taken at the discretion of the investigator.</time_frame>
        <population>Pharmacokinetic Analysis Set. AUC0-w24 could not be determined for 30 participants in the SAIT101 arm, 32 participants in the MabThera arm and 28 participants either in the Rituxan arm as either there was no concentration at the start and/or end time, the Week 24 sample was out of window or samples were missing.</population>
        <group_list>
          <group group_id="O1">
            <title>SAIT101</title>
            <description>1000 mg intravenous (iv) SAIT101 on Day 1 and 15 (Part A). 1000 mg iv SAIT101 on week 24 and 26 (Part B) for eligible participants,</description>
          </group>
          <group group_id="O2">
            <title>MabThera</title>
            <description>1000 mg iv MabThera on Day 1 and 15 (Part A). 1000 mg iv MabThera on week 24 and 26 (Part B) for eligible participants.</description>
          </group>
          <group group_id="O3">
            <title>Rituxan</title>
            <description>1000 mg iv of Rituxan on Day 1 and 15 (Part A). 1000 mg iv of Rituxan on week 24 and 26 (Part B) for eligible participants</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration Time Curve Week 2 to Week 24 (AUC(w2-24)</title>
          <description>Pharmacokinetic endpoint: Area under the concentration time curve week 2 to week 24 (AUC(w2-24) calculated by linear up/log down trapezoidal summation.</description>
          <population>Pharmacokinetic Analysis Set. AUC0-w24 could not be determined for 30 participants in the SAIT101 arm, 32 participants in the MabThera arm and 28 participants either in the Rituxan arm as either there was no concentration at the start and/or end time, the Week 24 sample was out of window or samples were missing.</population>
          <units>h*µg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="61"/>
                <count group_id="O3" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107300" spread="41.1"/>
                    <measurement group_id="O2" value="109200" spread="40.0"/>
                    <measurement group_id="O3" value="116000" spread="40.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Concentration Time Curve Day 0 to Week 12 (AUC(0-w12))</title>
        <description>Pharmacokinetic endpoint: Area under the concentration time curve Day 0 to Week 12 calculated by linear up/log down trapezoidal summation.</description>
        <time_frame>Samples for pharmacokinetic evaluation were taken at Baseline and Weeks 0, 1, 2, 3, 4, 8 and 12. Unscheduled visit samples were taken at the discretion of the investigator.</time_frame>
        <population>Pharmacokinetic Analysis Set. AUC0-w12 could not be determined for 1 participant in the SAIT101 arm, 4 participants in the MabThera arm and 1 participant in the Rituxan arm because samples were missing</population>
        <group_list>
          <group group_id="O1">
            <title>SAIT101</title>
            <description>1000 mg intravenous (iv) SAIT101 on Day 1 and 15 (Part A). 1000 mg iv SAIT101 on week 24 and 26 (Part B) for eligible participants,</description>
          </group>
          <group group_id="O2">
            <title>MabThera</title>
            <description>1000 mg iv MabThera on Day 1 and 15 (Part A). 1000 mg iv MabThera on week 24 and 26 (Part B) for eligible participants.</description>
          </group>
          <group group_id="O3">
            <title>Rituxan</title>
            <description>1000 mg iv of Rituxan on Day 1 and 15 (Part A). 1000 mg iv of Rituxan on week 24 and 26 (Part B) for eligible participants</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration Time Curve Day 0 to Week 12 (AUC(0-w12))</title>
          <description>Pharmacokinetic endpoint: Area under the concentration time curve Day 0 to Week 12 calculated by linear up/log down trapezoidal summation.</description>
          <population>Pharmacokinetic Analysis Set. AUC0-w12 could not be determined for 1 participant in the SAIT101 arm, 4 participants in the MabThera arm and 1 participant in the Rituxan arm because samples were missing</population>
          <units>h*µg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="93"/>
                <count group_id="O2" value="89"/>
                <count group_id="O3" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="148500" spread="33.1"/>
                    <measurement group_id="O2" value="157400" spread="30.3"/>
                    <measurement group_id="O3" value="155900" spread="33.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Maximum Plasma Concentration (Tmax) (Dose 1)</title>
        <description>Pharmacokinetic endpoint: Maximum plasma concentration over the first dosing interval obtained directly from the observed concentration versus time data.</description>
        <time_frame>Samples for pharmacokinetic evaluation were taken at Baseline and Weeks 0, 1, 2, 3, 4, 8, 12, 16, 20 and 24. Unscheduled visit samples were taken at the discretion of the investigator.</time_frame>
        <population>Pharmacokinetic Analysis Set. Tmax (dose 1) could not be determined for 1 participant in the SAIT101 arm, 1 patient in the MabThera arm and 2 participants in the Rituxan arm as samples were missing or set to missing due to initial or embedded Below the Limit of Quantification (BLQ)..</population>
        <group_list>
          <group group_id="O1">
            <title>SAIT101</title>
            <description>1000 mg intravenous (iv) SAIT101 on Day 1 and 15 (Part A). 1000 mg iv SAIT101 on week 24 and 26 (Part B) for eligible participants,</description>
          </group>
          <group group_id="O2">
            <title>MabThera</title>
            <description>1000 mg iv MabThera on Day 1 and 15 (Part A). 1000 mg iv MabThera on week 24 and 26 (Part B) for eligible participants.</description>
          </group>
          <group group_id="O3">
            <title>Rituxan</title>
            <description>1000 mg iv of Rituxan on Day 1 and 15 (Part A). 1000 mg iv of Rituxan on week 24 and 26 (Part B) for eligible participants</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Maximum Plasma Concentration (Tmax) (Dose 1)</title>
          <description>Pharmacokinetic endpoint: Maximum plasma concentration over the first dosing interval obtained directly from the observed concentration versus time data.</description>
          <population>Pharmacokinetic Analysis Set. Tmax (dose 1) could not be determined for 1 participant in the SAIT101 arm, 1 patient in the MabThera arm and 2 participants in the Rituxan arm as samples were missing or set to missing due to initial or embedded Below the Limit of Quantification (BLQ)..</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="93"/>
                <count group_id="O2" value="92"/>
                <count group_id="O3" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.167" lower_limit="3.00" upper_limit="6.50"/>
                    <measurement group_id="O2" value="5.167" lower_limit="3.00" upper_limit="358.75"/>
                    <measurement group_id="O3" value="4.500" lower_limit="3.00" upper_limit="6.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Maximum Plasma Concentration (Tmax) (Dose 2)</title>
        <description>Time of maximum concentration postinfusion over the second dosing interval, obtained directly from the observed concentration versus time data.</description>
        <time_frame>Samples for pharmacokinetic evaluation were taken at Baseline and Weeks 0, 1, 2, 3, 4, 8, 12, 16, 20 and 24. Unscheduled visit samples were taken at the discretion of the investigator.</time_frame>
        <population>Pharmacokinetic Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>SAIT101</title>
            <description>1000 mg intravenous (iv) SAIT101 on Day 1 and 15 (Part A). 1000 mg iv SAIT101 on week 24 and 26 (Part B) for eligible participants,</description>
          </group>
          <group group_id="O2">
            <title>MabThera</title>
            <description>1000 mg iv MabThera on Day 1 and 15 (Part A). 1000 mg iv MabThera on week 24 and 26 (Part B) for eligible participants.</description>
          </group>
          <group group_id="O3">
            <title>Rituxan</title>
            <description>1000 mg iv of Rituxan on Day 1 and 15 (Part A). 1000 mg iv of Rituxan on week 24 and 26 (Part B) for eligible participants</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Maximum Plasma Concentration (Tmax) (Dose 2)</title>
          <description>Time of maximum concentration postinfusion over the second dosing interval, obtained directly from the observed concentration versus time data.</description>
          <population>Pharmacokinetic Analysis Set</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
                <count group_id="O2" value="93"/>
                <count group_id="O3" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.167" lower_limit="2.92" upper_limit="5.50"/>
                    <measurement group_id="O2" value="4.167" lower_limit="0.00" upper_limit="48.08"/>
                    <measurement group_id="O3" value="4.250" lower_limit="2.92" upper_limit="23.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Terminal Rate Constant (λz)</title>
        <description>Pharmacokinetic endpoint: Apparent terminal rate constant (λz) determined by linear regression of the terminal points of the log-linear concentration-time curve. Best fit method followed by visual assessment was used to identify the terminal linear phase of the concentration-time profile. A minimum of 3 data points was used for determination.</description>
        <time_frame>Samples for pharmacokinetic evaluation were taken at Baseline and Weeks 0, 1, 2, 3, 4, 8, 12, 16, 20 and 24. Unscheduled visit samples were taken at the discretion of the investigator.</time_frame>
        <population>Pharmacokinetic Analysis Set. λz could not be determined for 1 participant in the SAIT101 arm, 2 participants in the MabThera arm and 1 participant in the Rituxan arm as either the terminal phase was undetermined or the Regulatory Scientific Quality (RSQ) was &lt;0.800.</population>
        <group_list>
          <group group_id="O1">
            <title>SAIT101</title>
            <description>1000 mg intravenous (iv) SAIT101 on Day 1 and 15 (Part A). 1000 mg iv SAIT101 on week 24 and 26 (Part B) for eligible participants,</description>
          </group>
          <group group_id="O2">
            <title>MabThera</title>
            <description>1000 mg iv MabThera on Day 1 and 15 (Part A). 1000 mg iv MabThera on week 24 and 26 (Part B) for eligible participants.</description>
          </group>
          <group group_id="O3">
            <title>Rituxan</title>
            <description>1000 mg iv of Rituxan on Day 1 and 15 (Part A). 1000 mg iv of Rituxan on week 24 and 26 (Part B) for eligible participants</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Terminal Rate Constant (λz)</title>
          <description>Pharmacokinetic endpoint: Apparent terminal rate constant (λz) determined by linear regression of the terminal points of the log-linear concentration-time curve. Best fit method followed by visual assessment was used to identify the terminal linear phase of the concentration-time profile. A minimum of 3 data points was used for determination.</description>
          <population>Pharmacokinetic Analysis Set. λz could not be determined for 1 participant in the SAIT101 arm, 2 participants in the MabThera arm and 1 participant in the Rituxan arm as either the terminal phase was undetermined or the Regulatory Scientific Quality (RSQ) was &lt;0.800.</population>
          <units>1/hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="93"/>
                <count group_id="O2" value="91"/>
                <count group_id="O3" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.002358" spread="0.00061132"/>
                    <measurement group_id="O2" value="0.002283" spread="0.00067311"/>
                    <measurement group_id="O3" value="0.002240" spread="0.00059435"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Systemic Clearance (CL)</title>
        <description>Pharmacokinetic endpoint: Systemic clearance (CL) over the first dosing period calculated as dose (first + second dose) divided by AUC(0-∞).</description>
        <time_frame>Samples for pharmacokinetic evaluation were taken at Baseline and Weeks 0, 1, 2, 3, 4, 8, 12, 16, 20 and 24. Unscheduled visit samples were taken at the discretion of the investigator.</time_frame>
        <population>Pharmacokinetic Analysis Set. CL could not be determined for 1 participant in the SAIT101 arm, 2 participants in the MabThera arm and 2 participants in the Rituxan arm as either the terminal phase was undetermined or the Regulatory Scientific Quality (RSQ) was &lt;0.800.</population>
        <group_list>
          <group group_id="O1">
            <title>SAIT101</title>
            <description>1000 mg intravenous (iv) SAIT101 on Day 1 and 15 (Part A). 1000 mg iv SAIT101 on week 24 and 26 (Part B) for eligible participants,</description>
          </group>
          <group group_id="O2">
            <title>MabThera</title>
            <description>1000 mg iv MabThera on Day 1 and 15 (Part A). 1000 mg iv MabThera on week 24 and 26 (Part B) for eligible participants.</description>
          </group>
          <group group_id="O3">
            <title>Rituxan</title>
            <description>1000 mg iv of Rituxan on Day 1 and 15 (Part A). 1000 mg iv of Rituxan on week 24 and 26 (Part B) for eligible participants</description>
          </group>
        </group_list>
        <measure>
          <title>Systemic Clearance (CL)</title>
          <description>Pharmacokinetic endpoint: Systemic clearance (CL) over the first dosing period calculated as dose (first + second dose) divided by AUC(0-∞).</description>
          <population>Pharmacokinetic Analysis Set. CL could not be determined for 1 participant in the SAIT101 arm, 2 participants in the MabThera arm and 2 participants in the Rituxan arm as either the terminal phase was undetermined or the Regulatory Scientific Quality (RSQ) was &lt;0.800.</population>
          <units>L/day</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="93"/>
                <count group_id="O2" value="91"/>
                <count group_id="O3" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01314" spread="34.6"/>
                    <measurement group_id="O2" value="0.01235" spread="29.0"/>
                    <measurement group_id="O3" value="0.01240" spread="33.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Volume of Distribution (VD)</title>
        <description>Pharmacokinetic endpoint: Volume of distribution (VD) over the first dosing period calculated as dose (first + second dose) divided by [λz AUC(0-∞)]</description>
        <time_frame>Samples for pharmacokinetic evaluation were taken at Baseline and Weeks 0, 1, 2, 3, 4, 8, 12, 16, 20 and 24. Unscheduled visit samples were taken at the discretion of the investigator.</time_frame>
        <population>Pharmacokinetic Analysis Set. VD could not be determined for 1 participant in the SAIT101 arm, 2 participants in the MabThera arm and 2 participants in the Rituxan arm as either the terminal phase was undetermined or the Regulatory Scientific Quality was &lt;0.800.</population>
        <group_list>
          <group group_id="O1">
            <title>SAIT101</title>
            <description>1000 mg intravenous (iv) SAIT101 on Day 1 and 15 (Part A). 1000 mg iv SAIT101 on week 24 and 26 (Part B) for eligible participants,</description>
          </group>
          <group group_id="O2">
            <title>MabThera</title>
            <description>1000 mg iv MabThera on Day 1 and 15 (Part A). 1000 mg iv MabThera on week 24 and 26 (Part B) for eligible participants.</description>
          </group>
          <group group_id="O3">
            <title>Rituxan</title>
            <description>1000 mg iv of Rituxan on Day 1 and 15 (Part A). 1000 mg iv of Rituxan on week 24 and 26 (Part B) for eligible participants</description>
          </group>
        </group_list>
        <measure>
          <title>Volume of Distribution (VD)</title>
          <description>Pharmacokinetic endpoint: Volume of distribution (VD) over the first dosing period calculated as dose (first + second dose) divided by [λz AUC(0-∞)]</description>
          <population>Pharmacokinetic Analysis Set. VD could not be determined for 1 participant in the SAIT101 arm, 2 participants in the MabThera arm and 2 participants in the Rituxan arm as either the terminal phase was undetermined or the Regulatory Scientific Quality was &lt;0.800.</population>
          <units>Litres (L)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="93"/>
                <count group_id="O2" value="91"/>
                <count group_id="O3" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.757" spread="28.0"/>
                    <measurement group_id="O2" value="5.635" spread="23.6"/>
                    <measurement group_id="O3" value="5.727" spread="22.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Terminal Half-life (T1/2)</title>
        <description>Pharmacokinetic endpoint: Terminal half-life determined as ln2/λz.</description>
        <time_frame>Samples for pharmacokinetic evaluation were taken at Baseline and Weeks 0, 1, 2, 3, 4, 8, 12, 16, 20 and 24. Unscheduled visit samples were taken at the discretion of the investigator.</time_frame>
        <population>Pharmacokinetic Analysis Set. T1/2 could not be determined for 1 participant in the SAIT101 arm, 2 participants in the MabThera arm and 1 participant in the Rituxan arm as either the terminal was undetermined or the Regulatory Scientific Quality was &lt;0.800.</population>
        <group_list>
          <group group_id="O1">
            <title>SAIT101</title>
            <description>1000 mg intravenous (iv) SAIT101 on Day 1 and 15 (Part A). 1000 mg iv SAIT101 on week 24 and 26 (Part B) for eligible participants,</description>
          </group>
          <group group_id="O2">
            <title>MabThera</title>
            <description>1000 mg iv MabThera on Day 1 and 15 (Part A). 1000 mg iv MabThera on week 24 and 26 (Part B) for eligible participants.</description>
          </group>
          <group group_id="O3">
            <title>Rituxan</title>
            <description>1000 mg iv of Rituxan on Day 1 and 15 (Part A). 1000 mg iv of Rituxan on week 24 and 26 (Part B) for eligible participants</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Half-life (T1/2)</title>
          <description>Pharmacokinetic endpoint: Terminal half-life determined as ln2/λz.</description>
          <population>Pharmacokinetic Analysis Set. T1/2 could not be determined for 1 participant in the SAIT101 arm, 2 participants in the MabThera arm and 1 participant in the Rituxan arm as either the terminal was undetermined or the Regulatory Scientific Quality was &lt;0.800.</population>
          <units>Hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="93"/>
                <count group_id="O2" value="91"/>
                <count group_id="O3" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="303.7" spread="26.1"/>
                    <measurement group_id="O2" value="316.1" spread="29.0"/>
                    <measurement group_id="O3" value="319.7" spread="26.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in DAS28-CRP at Weeks 8, 16, 36 and 52</title>
        <description>Disease Activity Score 28-C-Reactive Protein (DAS28-CRP) samples taken at Baseline and Weeks 8, 16, 24, 36 and 52. DAS28-CRP was calculated using the following equation: [0.56*Square Root (SQRT) (tender 28 joint count)+0.28*SQRT(swollen 28 joint count)+0.36*ln(CRP+1)]*1.10+1.15.
Total DAS28-CRP scores are presented and range from 2.0 (minimum) to 10 (maximum). Lower scores represent a better patient outcome. Disease remission is considered achieved if the score is between 0 and &lt;2.6. Low disease activity corresponds to 2.6 to &lt;3.2. Moderate activity is between 3.2 &amp; ≤5.1, while high activity is above 5.1.</description>
        <time_frame>Baseline and Weeks 8, 16, 24, 36 and 52 (EOS)</time_frame>
        <population>Full Analysis Set (analyses are reported in terms of the arm that the patient was initially randomised into. In the Rituxan arm only, patients eligible for treatment in Part B underwent a second randomisation to receive either Rituxan or SAIT101 and are reported in the Rituxan arm according to their initial randomisation).</population>
        <group_list>
          <group group_id="O1">
            <title>SAIT101</title>
            <description>1000 mg intravenous (iv) SAIT101 on Day 1 and 15 (Part A). 1000 mg iv SAIT101 on week 24 and 26 (Part B) for eligible participants,</description>
          </group>
          <group group_id="O2">
            <title>MabThera</title>
            <description>1000 mg iv MabThera on Day 1 and 15 (Part A). 1000 mg iv MabThera on week 24 and 26 (Part B) for eligible participants.</description>
          </group>
          <group group_id="O3">
            <title>Rituxan</title>
            <description>1000 mg iv of Rituxan on Day 1 and 15 (Part A). 1000 mg iv of Rituxan on week 24 and 26 (Part B) for eligible participants</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in DAS28-CRP at Weeks 8, 16, 36 and 52</title>
          <description>Disease Activity Score 28-C-Reactive Protein (DAS28-CRP) samples taken at Baseline and Weeks 8, 16, 24, 36 and 52. DAS28-CRP was calculated using the following equation: [0.56*Square Root (SQRT) (tender 28 joint count)+0.28*SQRT(swollen 28 joint count)+0.36*ln(CRP+1)]*1.10+1.15.
Total DAS28-CRP scores are presented and range from 2.0 (minimum) to 10 (maximum). Lower scores represent a better patient outcome. Disease remission is considered achieved if the score is between 0 and &lt;2.6. Low disease activity corresponds to 2.6 to &lt;3.2. Moderate activity is between 3.2 &amp; ≤5.1, while high activity is above 5.1.</description>
          <population>Full Analysis Set (analyses are reported in terms of the arm that the patient was initially randomised into. In the Rituxan arm only, patients eligible for treatment in Part B underwent a second randomisation to receive either Rituxan or SAIT101 and are reported in the Rituxan arm according to their initial randomisation).</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="97"/>
                <count group_id="O3" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (Baseline)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="98"/>
                    <count group_id="O2" value="97"/>
                    <count group_id="O3" value="98"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.282" spread="0.8899"/>
                    <measurement group_id="O2" value="5.288" spread="0.8073"/>
                    <measurement group_id="O3" value="5.170" spread="0.8326"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="93"/>
                    <count group_id="O2" value="93"/>
                    <count group_id="O3" value="93"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.405" spread="1.0189"/>
                    <measurement group_id="O2" value="4.324" spread="1.1132"/>
                    <measurement group_id="O3" value="4.251" spread="1.1392"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="93"/>
                    <count group_id="O2" value="93"/>
                    <count group_id="O3" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.001" spread="1.1116"/>
                    <measurement group_id="O2" value="4.155" spread="0.9750"/>
                    <measurement group_id="O3" value="4.100" spread="1.0044"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="91"/>
                    <count group_id="O2" value="88"/>
                    <count group_id="O3" value="85"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.300" spread="1.0331"/>
                    <measurement group_id="O2" value="4.463" spread="1.0648"/>
                    <measurement group_id="O3" value="4.443" spread="0.9774"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="90"/>
                    <count group_id="O2" value="83"/>
                    <count group_id="O3" value="84"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.552" spread="1.1452"/>
                    <measurement group_id="O2" value="3.823" spread="0.9290"/>
                    <measurement group_id="O3" value="3.716" spread="1.0684"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (End of Study(</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="92"/>
                    <count group_id="O2" value="88"/>
                    <count group_id="O3" value="87"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.660" spread="1.2636"/>
                    <measurement group_id="O2" value="3.754" spread="1.3037"/>
                    <measurement group_id="O3" value="3.518" spread="1.1276"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 52 (EOS). Least square means and confidence intervals were estimated from an ANCOVA model containing treatment group as a factor and Baseline DAS28-CRP value as a covariate. ANCOVA model contains treatment group only.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.6068</p_value>
            <method>ANCOVA</method>
            <param_type>LS Means Difference</param_type>
            <param_value>-0.09</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.172</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.428</ci_lower_limit>
            <ci_upper_limit>0.250</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 52 (EOS) Least square means and confidence intervals were estimated from an ANCOVA model containing treatment group as a factor and Baseline DAS28-CRP value as a covariate. ANCOVA model contains treatment group only.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.5990</p_value>
            <method>ANCOVA</method>
            <param_type>LS Means Difference</param_type>
            <param_value>0.09</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.172</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.249</ci_lower_limit>
            <ci_upper_limit>0.430</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 53 (EOS) MabThera vs Rituxan. Least square means and confidence intervals were estimated from an ANCOVA model containing treatment group as a factor and Baseline DAS28-CRP value as a covariate. ANCOVA model contains treatment group only.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.3053</p_value>
            <method>ANCOVA</method>
            <param_type>LS Means Difference</param_type>
            <param_value>0.18</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.175</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.165</ci_lower_limit>
            <ci_upper_limit>0.532</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>American Collage of Rheumatology 20% Response Criteria (ACR20) Response Rates at Weeks 8, 16, 24, 36 and 52</title>
        <description>American Collage of Rheumatology (ACR) 20% response criteria (ACR20) response rates were assessed at Baseline and Weeks 8, 16, 24, 36 and 52.
An ACR20 response is defined as both improvement of 20% in the number of tender and number of swollen joints, and a 20% improvement in three of the following five criteria: patient global assessment, physician global assessment, functional ability measure [Health Assessment Questionnaire (HAQ)], visual analogue pain scale, and erythrocyte sedimentation rate or C-reactive protein (CRP).</description>
        <time_frame>Baseline and Weeks 8, 16, 24, 36 and 52 (EOS)</time_frame>
        <population>Full Analysis Set (analyses are reported in terms of the arm that the patient was initially randomised into. In the Rituxan arm only, patients eligible for treatment in Part B underwent a second randomisation to receive either Rituxan or SAIT101 and are reported in the Rituxan arm according to their initial randomisation).</population>
        <group_list>
          <group group_id="O1">
            <title>SAIT101</title>
            <description>1000 mg intravenous (iv) SAIT101 on Day 1 and 15 (Part A). 1000 mg iv SAIT101 on week 24 and 26 (Part B) for eligible participants,</description>
          </group>
          <group group_id="O2">
            <title>MabThera</title>
            <description>1000 mg iv MabThera on Day 1 and 15 (Part A). 1000 mg iv MabThera on week 24 and 26 (Part B) for eligible participants.</description>
          </group>
          <group group_id="O3">
            <title>Rituxan</title>
            <description>1000 mg iv of Rituxan on Day 1 and 15 (Part A). 1000 mg iv of Rituxan on week 24 and 26 (Part B) for eligible participants</description>
          </group>
        </group_list>
        <measure>
          <title>American Collage of Rheumatology 20% Response Criteria (ACR20) Response Rates at Weeks 8, 16, 24, 36 and 52</title>
          <description>American Collage of Rheumatology (ACR) 20% response criteria (ACR20) response rates were assessed at Baseline and Weeks 8, 16, 24, 36 and 52.
An ACR20 response is defined as both improvement of 20% in the number of tender and number of swollen joints, and a 20% improvement in three of the following five criteria: patient global assessment, physician global assessment, functional ability measure [Health Assessment Questionnaire (HAQ)], visual analogue pain scale, and erythrocyte sedimentation rate or C-reactive protein (CRP).</description>
          <population>Full Analysis Set (analyses are reported in terms of the arm that the patient was initially randomised into. In the Rituxan arm only, patients eligible for treatment in Part B underwent a second randomisation to receive either Rituxan or SAIT101 and are reported in the Rituxan arm according to their initial randomisation).</population>
          <units>participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="98"/>
                <count group_id="O3" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ACR20 Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="95"/>
                    <count group_id="O2" value="93"/>
                    <count group_id="O3" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39" lower_limit="31.70" upper_limit="51.10"/>
                    <measurement group_id="O2" value="33" lower_limit="26.51" upper_limit="45.61"/>
                    <measurement group_id="O3" value="44" lower_limit="37.91" upper_limit="57.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR20 Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="94"/>
                    <count group_id="O2" value="92"/>
                    <count group_id="O3" value="91"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50" lower_limit="43.18" upper_limit="62.95"/>
                    <measurement group_id="O2" value="54" lower_limit="48.48" upper_limit="68.21"/>
                    <measurement group_id="O3" value="53" lower_limit="47.98" upper_limit="67.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR20 Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="92"/>
                    <count group_id="O2" value="87"/>
                    <count group_id="O3" value="86"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36" lower_limit="28.79" upper_limit="49.35"/>
                    <measurement group_id="O2" value="31" lower_limit="26.37" upper_limit="46.11"/>
                    <measurement group_id="O3" value="34" lower_limit="29.86" upper_limit="50.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR20 Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="90"/>
                    <count group_id="O2" value="82"/>
                    <count group_id="O3" value="83"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63" lower_limit="59.87" upper_limit="78.49"/>
                    <measurement group_id="O2" value="47" lower_limit="46.52" upper_limit="67.46"/>
                    <measurement group_id="O3" value="58" lower_limit="58.00" upper_limit="78.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR20 Week 52 (EOS)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="94"/>
                    <count group_id="O2" value="90"/>
                    <count group_id="O3" value="89"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60" lower_limit="53.75" upper_limit="72.82"/>
                    <measurement group_id="O2" value="49" lower_limit="44.18" upper_limit="64.34"/>
                    <measurement group_id="O3" value="59" lower_limit="55.98" upper_limit="75.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 52 (EOS) assessment. The 95% CIs for ACR response rate and difference were derived using the Wilson Score method.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference (%)</param_type>
            <param_value>9.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>7.22</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.74</ci_lower_limit>
            <ci_upper_limit>23.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 52 (EOS) assessment. The 95% CIs for ACR response rate and difference were derived using the Wilson Score method.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference (%)</param_type>
            <param_value>-2.5</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>7.05</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-15.95</ci_lower_limit>
            <ci_upper_limit>11.22</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 52 (EOS) assessment. The 95% CIs for ACR response rate and difference were derived using the Wilson Score method.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference (%)</param_type>
            <param_value>-11.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>7.26</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-25.47</ci_lower_limit>
            <ci_upper_limit>2.45</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>American Collage of Rheumatology 50% Response Criteria (ACR50) Response Rates and American Collage of Rheumatology 70% Response Criteria (ACR70) at Weeks 8, 16, 24, 36 and 52</title>
        <description>Efficacy endpoint: American Collage of Rheumatology 50% response criteria (ACR50) response rates and American Collage of Rheumatology 70% response criteria (ACR70) at weeks 8, 16, 24, 36 and 52.
An ACR50 response is defined as both improvement of 50% in the number of tender and number of swollen joints, and a 50% improvement in three of the following five criteria: patient global assessment, physician global assessment, functional ability measure [Health Assessment Questionnaire (HAQ)], visual analogue pain scale, and erythrocyte sedimentation rate or C-reactive protein (CRP).
An ACR70 response is defined as both improvement of 70% in the number of tender and number of swollen joints, and a 70% improvement in three of the following five criteria: patient global assessment, physician global assessment, functional ability measure [Health Assessment Questionnaire (HAQ)], visual analogue pain scale, and erythrocyte sedimentation rate or C-reactive protein (CRP).</description>
        <time_frame>Baseline and Weeks 8, 16, 24, 36 and 52 (EOS)</time_frame>
        <population>Full Analysis Set (analyses are reported in terms of the arm that the patient was initially randomised into. In the Rituxan arm only, patients eligible for treatment in Part B underwent a second randomisation to receive either Rituxan or SAIT101 and are reported in the Rituxan arm according to their initial randomisation).</population>
        <group_list>
          <group group_id="O1">
            <title>SAIT101</title>
            <description>1000 mg intravenous (iv) SAIT101 on Day 1 and 15 (Part A). 1000 mg iv SAIT101 on week 24 and 26 (Part B) for eligible participants,</description>
          </group>
          <group group_id="O2">
            <title>MabThera</title>
            <description>1000 mg iv MabThera on Day 1 and 15 (Part A). 1000 mg iv MabThera on week 24 and 26 (Part B) for eligible participants.</description>
          </group>
          <group group_id="O3">
            <title>Rituxan</title>
            <description>1000 mg iv of Rituxan on Day 1 and 15 (Part A). 1000 mg iv of Rituxan on week 24 and 26 (Part B) for eligible participants</description>
          </group>
        </group_list>
        <measure>
          <title>American Collage of Rheumatology 50% Response Criteria (ACR50) Response Rates and American Collage of Rheumatology 70% Response Criteria (ACR70) at Weeks 8, 16, 24, 36 and 52</title>
          <description>Efficacy endpoint: American Collage of Rheumatology 50% response criteria (ACR50) response rates and American Collage of Rheumatology 70% response criteria (ACR70) at weeks 8, 16, 24, 36 and 52.
An ACR50 response is defined as both improvement of 50% in the number of tender and number of swollen joints, and a 50% improvement in three of the following five criteria: patient global assessment, physician global assessment, functional ability measure [Health Assessment Questionnaire (HAQ)], visual analogue pain scale, and erythrocyte sedimentation rate or C-reactive protein (CRP).
An ACR70 response is defined as both improvement of 70% in the number of tender and number of swollen joints, and a 70% improvement in three of the following five criteria: patient global assessment, physician global assessment, functional ability measure [Health Assessment Questionnaire (HAQ)], visual analogue pain scale, and erythrocyte sedimentation rate or C-reactive protein (CRP).</description>
          <population>Full Analysis Set (analyses are reported in terms of the arm that the patient was initially randomised into. In the Rituxan arm only, patients eligible for treatment in Part B underwent a second randomisation to receive either Rituxan or SAIT101 and are reported in the Rituxan arm according to their initial randomisation).</population>
          <units>participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="98"/>
                <count group_id="O3" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ACR50 Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="95"/>
                    <count group_id="O2" value="93"/>
                    <count group_id="O3" value="93"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13" lower_limit="8.17" upper_limit="22.02"/>
                    <measurement group_id="O2" value="11" lower_limit="6.73" upper_limit="19.95"/>
                    <measurement group_id="O3" value="14" lower_limit="9.29" upper_limit="23.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR70 Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="95"/>
                    <count group_id="O2" value="93"/>
                    <count group_id="O3" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="0.58" upper_limit="7.35"/>
                    <measurement group_id="O2" value="2" lower_limit="0.59" upper_limit="7.51"/>
                    <measurement group_id="O3" value="2" lower_limit="0.60" upper_limit="7.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR50 Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="94"/>
                    <count group_id="O2" value="92"/>
                    <count group_id="O3" value="91"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17" lower_limit="11.61" upper_limit="27.07"/>
                    <measurement group_id="O2" value="16" lower_limit="11.00" upper_limit="26.40"/>
                    <measurement group_id="O3" value="14" lower_limit="9.39" upper_limit="24.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR70 Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="94"/>
                    <count group_id="O2" value="92"/>
                    <count group_id="O3" value="91"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9" lower_limit="5.12" upper_limit="17.20"/>
                    <measurement group_id="O2" value="4" lower_limit="1.70" upper_limit="10.65"/>
                    <measurement group_id="O3" value="5" lower_limit="2.37" upper_limit="12.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR50 Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="92"/>
                    <count group_id="O2" value="87"/>
                    <count group_id="O3" value="86"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15" lower_limit="10.14" upper_limit="25.17"/>
                    <measurement group_id="O2" value="8" lower_limit="4.73" upper_limit="17.11"/>
                    <measurement group_id="O3" value="5" lower_limit="2.51" upper_limit="12.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR70 Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="92"/>
                    <count group_id="O2" value="87"/>
                    <count group_id="O3" value="86"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8" lower_limit="4.47" upper_limit="16.23"/>
                    <measurement group_id="O2" value="2" lower_limit="0.63" upper_limit="8.00"/>
                    <measurement group_id="O3" value="3" lower_limit="1.19" upper_limit="9.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR50 Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="90"/>
                    <count group_id="O2" value="82"/>
                    <count group_id="O3" value="83"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37" lower_limit="31.51" upper_limit="51.44"/>
                    <measurement group_id="O2" value="19" lower_limit="15.37" upper_limit="33.38"/>
                    <measurement group_id="O3" value="25" lower_limit="21.31" upper_limit="40.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR70 Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="90"/>
                    <count group_id="O2" value="82"/>
                    <count group_id="O3" value="83"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19" lower_limit="13.95" upper_limit="30.63"/>
                    <measurement group_id="O2" value="6" lower_limit="3.40" upper_limit="15.06"/>
                    <measurement group_id="O3" value="12" lower_limit="8.47" upper_limit="23.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR50 Week 52 (EOS)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="94"/>
                    <count group_id="O2" value="90"/>
                    <count group_id="O3" value="89"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35" lower_limit="28.14" upper_limit="47.33"/>
                    <measurement group_id="O2" value="25" lower_limit="19.58" upper_limit="37.80"/>
                    <measurement group_id="O3" value="30" lower_limit="24.74" upper_limit="44.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR70 Week 52 (EOS)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="94"/>
                    <count group_id="O2" value="90"/>
                    <count group_id="O3" value="89"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23" lower_limit="16.89" upper_limit="34.05"/>
                    <measurement group_id="O2" value="13" lower_limit="8.64" upper_limit="23.16"/>
                    <measurement group_id="O3" value="17" lower_limit="12.28" upper_limit="28.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>ACR20 Week 52 (EOS) assessment. The 95% CIs for ACR response rate and difference were derived using the Wilson Score method. The adjusted difference and its 95% confidence intervals are from a logistic regression model containing treatment group as a factor and baseline DAS28-CRP value as a covariate.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference (%)</param_type>
            <param_value>9.5</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.87</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.07</ci_lower_limit>
            <ci_upper_limit>22.46</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>ACR50 Week 52 (EOS) assessment. The 95% CIs for ACR response rate and difference were derived using the Wilson Score method. The adjusted difference and its 95% confidence intervals are from a logistic regression model containing treatment group as a factor and baseline DAS28-CRP value as a covariate.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference (%)</param_type>
            <param_value>3.5</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>7.07</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.22</ci_lower_limit>
            <ci_upper_limit>17.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>ACR50 Week 52 (EOS) assessment. The 95% CIs for ACR response rate and difference were derived using the Wilson Score method. The adjusted difference and its 95% confidence intervals are from a logistic regression model containing treatment group as a factor and baseline DAS28-CRP value as a covariate.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference (%)</param_type>
            <param_value>-5.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.88</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-19.10</ci_lower_limit>
            <ci_upper_limit>7.51</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>ACR70 Week 52 (EOS) assessment. The 95% CIs for ACR response rate and difference were derived using the Wilson Score method. The adjusted difference and its 95% confidence intervals are from a logistic regression model containing treatment group as a factor and baseline DAS28-CRP value as a covariate.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference (%)</param_type>
            <param_value>10.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.78</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.52</ci_lower_limit>
            <ci_upper_limit>21.22</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>ACR70 Week 52 (EOS) assessment. The 95% CIs for ACR response rate and difference were derived using the Wilson Score method. The adjusted difference and its 95% confidence intervals are from a logistic regression model containing treatment group as a factor and baseline DAS28-CRP value as a covariate.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>5.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.08</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.69</ci_lower_limit>
            <ci_upper_limit>17.13</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>ACR70 Week 52 (EOS) assessment. The 95% CIs for ACR response rate and difference were derived using the Wilson Score method. The adjusted difference and its 95% confidence intervals are from a logistic regression model containing treatment group as a factor and baseline DAS28-CRP value as a covariate.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference (%)</param_type>
            <param_value>-4.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.58</dispersion_value>
            <ci_percent>92</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-15.68</ci_lower_limit>
            <ci_upper_limit>6.41</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Individual Components of the ACR Improvement Criteria on Day 1 and at Weeks 8, 16, 24, 36 and 52: Swollen Joint Count (SJC) and Tender Joint Count (TJC) (the 66/68 Joint Count System)</title>
        <description>Efficacy endpoint: Individual components of the ACR improvement criteria on Day 1 and at weeks 8, 16, 24, 36 and 52: Swollen Joint Count (SJC) and tender joint count (TJC) (the 66/68 joint count system). SJC and TJC assess the level of skeletal disease involvement. The 66/68 Joint Count evaluates 66 joints for swelling and 68 joints for tenderness.</description>
        <time_frame>Baseline and Weeks 8, 16, 24, 36 and 52 (EOS)</time_frame>
        <population>Full Analysis Set (analyses are reported in terms of the arm that the patient was initially randomised into. In the Rituxan arm only, patients eligible for treatment in Part B underwent a second randomisation to receive either Rituxan or SAIT101 and are reported in the Rituxan arm according to their initial randomisation).</population>
        <group_list>
          <group group_id="O1">
            <title>SAIT101</title>
            <description>1000 mg intravenous (iv) SAIT101 on Day 1 and 15 (Part A). 1000 mg iv SAIT101 on week 24 and 26 (Part B) for eligible participants,</description>
          </group>
          <group group_id="O2">
            <title>MabThera</title>
            <description>1000 mg iv MabThera on Day 1 and 15 (Part A). 1000 mg iv MabThera on week 24 and 26 (Part B) for eligible participants.</description>
          </group>
          <group group_id="O3">
            <title>Rituxan</title>
            <description>1000 mg iv of Rituxan on Day 1 and 15 (Part A). 1000 mg iv of Rituxan on week 24 and 26 (Part B) for eligible participants</description>
          </group>
        </group_list>
        <measure>
          <title>Individual Components of the ACR Improvement Criteria on Day 1 and at Weeks 8, 16, 24, 36 and 52: Swollen Joint Count (SJC) and Tender Joint Count (TJC) (the 66/68 Joint Count System)</title>
          <description>Efficacy endpoint: Individual components of the ACR improvement criteria on Day 1 and at weeks 8, 16, 24, 36 and 52: Swollen Joint Count (SJC) and tender joint count (TJC) (the 66/68 joint count system). SJC and TJC assess the level of skeletal disease involvement. The 66/68 Joint Count evaluates 66 joints for swelling and 68 joints for tenderness.</description>
          <population>Full Analysis Set (analyses are reported in terms of the arm that the patient was initially randomised into. In the Rituxan arm only, patients eligible for treatment in Part B underwent a second randomisation to receive either Rituxan or SAIT101 and are reported in the Rituxan arm according to their initial randomisation).</population>
          <units>Joints</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="98"/>
                <count group_id="O3" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Swollen Joint Count Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="98"/>
                    <count group_id="O2" value="97"/>
                    <count group_id="O3" value="98"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.2" spread="7.97"/>
                    <measurement group_id="O2" value="15.2" spread="15.2"/>
                    <measurement group_id="O3" value="13.0" spread="6.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swollen Joint Count Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="95"/>
                    <count group_id="O2" value="94"/>
                    <count group_id="O3" value="93"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.6" spread="7.11"/>
                    <measurement group_id="O2" value="8.4" spread="6.62"/>
                    <measurement group_id="O3" value="7.7" spread="5.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swollen Joint Count 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="94"/>
                    <count group_id="O2" value="93"/>
                    <count group_id="O3" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.5" spread="4.86"/>
                    <measurement group_id="O2" value="7.8" spread="7.20"/>
                    <measurement group_id="O3" value="7.0" spread="5.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swollen Joint Count 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="92"/>
                    <count group_id="O2" value="88"/>
                    <count group_id="O3" value="87"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.5" spread="5.13"/>
                    <measurement group_id="O2" value="10.0" spread="5.85"/>
                    <measurement group_id="O3" value="10.0" spread="6.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swollen Joint Count 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="90"/>
                    <count group_id="O2" value="83"/>
                    <count group_id="O3" value="85"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8" spread="6.21"/>
                    <measurement group_id="O2" value="5.4" spread="5.72"/>
                    <measurement group_id="O3" value="5.7" spread="5.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swollen Joint Count Week 52 (EOS)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="94"/>
                    <count group_id="O2" value="91"/>
                    <count group_id="O3" value="90"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.2" spread="6.53"/>
                    <measurement group_id="O2" value="6.5" spread="9.46"/>
                    <measurement group_id="O3" value="4.6" spread="5.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tender Joint Count Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="98"/>
                    <count group_id="O2" value="97"/>
                    <count group_id="O3" value="98"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.7" spread="11.08"/>
                    <measurement group_id="O2" value="22.6" spread="13.66"/>
                    <measurement group_id="O3" value="20.0" spread="10.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tender Joint Score Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="95"/>
                    <count group_id="O2" value="94"/>
                    <count group_id="O3" value="93"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.9" spread="9.94"/>
                    <measurement group_id="O2" value="14.0" spread="9.94"/>
                    <measurement group_id="O3" value="13.5" spread="10.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tender Joint Count Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="94"/>
                    <count group_id="O2" value="93"/>
                    <count group_id="O3" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.1" spread="10.24"/>
                    <measurement group_id="O2" value="12.5" spread="8.36"/>
                    <measurement group_id="O3" value="11.8" spread="9.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tender Joint Score Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="92"/>
                    <count group_id="O2" value="88"/>
                    <count group_id="O3" value="87"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.6" spread="9.79"/>
                    <measurement group_id="O2" value="15.6" spread="11.94"/>
                    <measurement group_id="O3" value="15.2" spread="11.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tender Joint Score Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="90"/>
                    <count group_id="O2" value="83"/>
                    <count group_id="O3" value="85"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3" spread="9.10"/>
                    <measurement group_id="O2" value="10.9" spread="10.68"/>
                    <measurement group_id="O3" value="9.6" spread="10.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tender Joint Score Week 52 (EOS)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="94"/>
                    <count group_id="O2" value="91"/>
                    <count group_id="O3" value="90"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.3" spread="9.34"/>
                    <measurement group_id="O2" value="11.9" spread="15.18"/>
                    <measurement group_id="O3" value="9.4" spread="11.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Swollen Joint Count (SJC) Week 52 (EOS) assessment. Least square means and confidence intervals were estimated from an ANCOVA model containing treatment group as a factor and baseline value as a covariate.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.1997</p_value>
            <method>ANCOVA</method>
            <param_type>LS Means Difference</param_type>
            <param_value>-1.28</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.991</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.230</ci_lower_limit>
            <ci_upper_limit>0.671</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Swollen Joint Count (SJC) Week 52 (EOS) assessment. Least square means and confidence intervals were estimated from an ANCOVA model containing treatment group as a factor and baseline value as a covariate.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.9098</p_value>
            <method>ANCOVA</method>
            <param_type>LS Means Difference</param_type>
            <param_value>-0.11</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.996</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.074</ci_lower_limit>
            <ci_upper_limit>1.848</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Swollen Joint Count (SJC) Week 52 (EOS) assessment. Least square means and confidence intervals were estimated from an ANCOVA model containing treatment group as a factor and baseline value as a covariate.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.2480</p_value>
            <method>ANCOVA</method>
            <param_type>LS Means Difference</param_type>
            <param_value>1.17</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.008</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.817</ci_lower_limit>
            <ci_upper_limit>3.150</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Tender Joint Count (TJC) Week 52 (EOS) assessment. Least square means and confidence intervals were estimated from an ANCOVA model containing treatment group as a factor and baseline value as a covariate.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.1931</p_value>
            <method>ANCOVA</method>
            <param_type>LS Means Difference</param_type>
            <param_value>-1.96</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.500</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.909</ci_lower_limit>
            <ci_upper_limit>0.996</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Swollen Joint Count (SJC) Week 52 (EOS) assessment. Least square means and confidence intervals were estimated from an ANCOVA model containing treatment group as a factor and baseline value as a covariate.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>-0.77</p_value>
            <method>ANCOVA</method>
            <param_type>LS Means Difference</param_type>
            <param_value>-0.77</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.500</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.722</ci_lower_limit>
            <ci_upper_limit>2.184</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Swollen Joint Count (SJC) Week 52 (EOS) assessment. Least square means and confidence intervals were estimated from an ANCOVA model containing treatment group as a factor and baseline value as a covariate.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.4352</p_value>
            <method>ANCOVA</method>
            <param_type>LS Means Difference</param_type>
            <param_value>1.19</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.520</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.805</ci_lower_limit>
            <ci_upper_limit>4.180</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Individual Components of the ACR Improvement Criteria on Day 1 and at Weeks 8, 16, 24, 36 and 52: Physicians Global Assessment of Disease Activity (Assessed on 1 to 100 mm Visual Analog Scale [VAS])</title>
        <description>Efficacy endpoint: Individual Components of the ACR Improvement Criteria on Day 1 and at Weeks 8, 16, 24, 36 and 52: Physicians global assessment of disease activity (assessed on 1 to 100 mm Visual Analog Scale [VAS]). Where 0 = no disease activity and 100 = maximum disease activity.</description>
        <time_frame>Baseline and Weeks 8, 16, 24, 36 and 52 (EOS)</time_frame>
        <population>Full Analysis Set (analyses are reported in terms of the arm that the patient was initially randomised into. In the Rituxan arm only, patients eligible for treatment in Part B underwent a second randomisation to receive either Rituxan or SAIT101 and are reported in the Rituxan arm according to their initial randomisation).</population>
        <group_list>
          <group group_id="O1">
            <title>SAIT101</title>
            <description>1000 mg intravenous (iv) SAIT101 on Day 1 and 15 (Part A). 1000 mg iv SAIT101 on week 24 and 26 (Part B) for eligible participants,</description>
          </group>
          <group group_id="O2">
            <title>MabThera</title>
            <description>1000 mg iv MabThera on Day 1 and 15 (Part A). 1000 mg iv MabThera on week 24 and 26 (Part B) for eligible participants.</description>
          </group>
          <group group_id="O3">
            <title>Rituxan</title>
            <description>1000 mg iv of Rituxan on Day 1 and 15 (Part A). 1000 mg iv of Rituxan on week 24 and 26 (Part B) for eligible participants</description>
          </group>
        </group_list>
        <measure>
          <title>Individual Components of the ACR Improvement Criteria on Day 1 and at Weeks 8, 16, 24, 36 and 52: Physicians Global Assessment of Disease Activity (Assessed on 1 to 100 mm Visual Analog Scale [VAS])</title>
          <description>Efficacy endpoint: Individual Components of the ACR Improvement Criteria on Day 1 and at Weeks 8, 16, 24, 36 and 52: Physicians global assessment of disease activity (assessed on 1 to 100 mm Visual Analog Scale [VAS]). Where 0 = no disease activity and 100 = maximum disease activity.</description>
          <population>Full Analysis Set (analyses are reported in terms of the arm that the patient was initially randomised into. In the Rituxan arm only, patients eligible for treatment in Part B underwent a second randomisation to receive either Rituxan or SAIT101 and are reported in the Rituxan arm according to their initial randomisation).</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="98"/>
                <count group_id="O3" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Disease Activty iDay 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="97"/>
                    <count group_id="O2" value="97"/>
                    <count group_id="O3" value="98"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.0" spread="14.30"/>
                    <measurement group_id="O2" value="69.4" spread="15.00"/>
                    <measurement group_id="O3" value="69.8" spread="14.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Activity Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="95"/>
                    <count group_id="O2" value="93"/>
                    <count group_id="O3" value="91"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.6" spread="20.75"/>
                    <measurement group_id="O2" value="43.2" spread="23.86"/>
                    <measurement group_id="O3" value="44.6" spread="23.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Activtiy Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="93"/>
                    <count group_id="O2" value="93"/>
                    <count group_id="O3" value="91"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.2" spread="20.94"/>
                    <measurement group_id="O2" value="39.0" spread="20.97"/>
                    <measurement group_id="O3" value="42.3" spread="20.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Activity Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="91"/>
                    <count group_id="O2" value="87"/>
                    <count group_id="O3" value="87"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.9" spread="22.28"/>
                    <measurement group_id="O2" value="47.8" spread="20.25"/>
                    <measurement group_id="O3" value="49.0" spread="22.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Activtiy Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="90"/>
                    <count group_id="O2" value="83"/>
                    <count group_id="O3" value="86"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.3" spread="21.56"/>
                    <measurement group_id="O2" value="36.3" spread="21.71"/>
                    <measurement group_id="O3" value="31.4" spread="20.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Activity Week 52 (EOS)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="94"/>
                    <count group_id="O2" value="91"/>
                    <count group_id="O3" value="90"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.1" spread="21.67"/>
                    <measurement group_id="O2" value="35.1" spread="23.49"/>
                    <measurement group_id="O3" value="31.2" spread="22.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 52 (EOS) Physician's Disease Activity Assessment. Least square means and confidence intervals were estimated from an ANCOVA model containing treatment group as a factor and baseline value as a covariate. Change from Study Day 1 (Baseline)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.2008</p_value>
            <method>ANCOVA</method>
            <param_type>LS Means Difference</param_type>
            <param_value>-4.16</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.242</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.541</ci_lower_limit>
            <ci_upper_limit>2.226</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 52 (EOS) Physician's Disease Activity Assessment. Least square means and confidence intervals were estimated from an ANCOVA model containing treatment group as a factor and baseline value as a covariate. Change from Study Day 1 (Baseline</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>-0.39</p_value>
            <method>ANOVA</method>
            <param_type>LS Means Difference</param_type>
            <param_value>-0.39</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.242</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.771</ci_lower_limit>
            <ci_upper_limit>5.994</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 52 (EOS) Physician's Disease Activity Assessment. Least square means and confidence intervals were estimated from an ANCOVA model containing treatment group as a factor and baseline value as a covariate. Change from Study Day 1 (Baseline</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.2498</p_value>
            <method>ANCOVA</method>
            <param_type>LS Means Difference</param_type>
            <param_value>3.77</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.268</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.665</ci_lower_limit>
            <ci_upper_limit>10.204</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Individual Components of the ACR Improvement Criteria on Day 1 and at Weeks 8, 16, 24, 36 and 52: Participants Assessment of Pain (Assessed on 1 to 100 mm Visual Analog Scale [VAS])</title>
        <description>Participants assessment of pain (assessed on 1 to 100 mm Visual Analog Scale [VAS]). Participants assessment of pain (assessed on 1 to 100 mm Visual Analog Scale [VAS]) where 0 = no pain and 100 = severe pain.</description>
        <time_frame>Baseline and Weeks 8, 16, 24, 36 and 52 (EOS)</time_frame>
        <population>Full Analysis Set (analyses are reported in terms of the arm that the patient was initially randomised into. In the Rituxan arm only, patients eligible for treatment in Part B underwent a second randomisation to receive either Rituxan or SAIT101 and are reported in the Rituxan arm according to their initial randomisation).</population>
        <group_list>
          <group group_id="O1">
            <title>SAIT101</title>
            <description>1000 mg intravenous (iv) SAIT101 on Day 1 and 15 (Part A). 1000 mg iv SAIT101 on week 24 and 26 (Part B) for eligible participants,</description>
          </group>
          <group group_id="O2">
            <title>MabThera</title>
            <description>1000 mg iv MabThera on Day 1 and 15 (Part A). 1000 mg iv MabThera on week 24 and 26 (Part B) for eligible participants.</description>
          </group>
          <group group_id="O3">
            <title>Rituxan</title>
            <description>1000 mg iv of Rituxan on Day 1 and 15 (Part A). 1000 mg iv of Rituxan on week 24 and 26 (Part B) for eligible participants</description>
          </group>
        </group_list>
        <measure>
          <title>Individual Components of the ACR Improvement Criteria on Day 1 and at Weeks 8, 16, 24, 36 and 52: Participants Assessment of Pain (Assessed on 1 to 100 mm Visual Analog Scale [VAS])</title>
          <description>Participants assessment of pain (assessed on 1 to 100 mm Visual Analog Scale [VAS]). Participants assessment of pain (assessed on 1 to 100 mm Visual Analog Scale [VAS]) where 0 = no pain and 100 = severe pain.</description>
          <population>Full Analysis Set (analyses are reported in terms of the arm that the patient was initially randomised into. In the Rituxan arm only, patients eligible for treatment in Part B underwent a second randomisation to receive either Rituxan or SAIT101 and are reported in the Rituxan arm according to their initial randomisation).</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="98"/>
                <count group_id="O3" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Assessment of Pain Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="98"/>
                    <count group_id="O2" value="98"/>
                    <count group_id="O3" value="97"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.0" spread="18.71"/>
                    <measurement group_id="O2" value="68.8" spread="20.02"/>
                    <measurement group_id="O3" value="68.8" spread="19.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Assessment of Pain Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="95"/>
                    <count group_id="O2" value="93"/>
                    <count group_id="O3" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.4" spread="22.79"/>
                    <measurement group_id="O2" value="50.4" spread="22.40"/>
                    <measurement group_id="O3" value="47.9" spread="23.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Assessment of Pain Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="94"/>
                    <count group_id="O2" value="91"/>
                    <count group_id="O3" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.7" spread="23.34"/>
                    <measurement group_id="O2" value="44.6" spread="20.91"/>
                    <measurement group_id="O3" value="44.4" spread="22.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Assessment of Pain Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="92"/>
                    <count group_id="O2" value="88"/>
                    <count group_id="O3" value="86"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.3" spread="24.15"/>
                    <measurement group_id="O2" value="51.6" spread="21.44"/>
                    <measurement group_id="O3" value="51.8" spread="23.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Assessment of Pain Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="90"/>
                    <count group_id="O2" value="83"/>
                    <count group_id="O3" value="84"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.8" spread="24.56"/>
                    <measurement group_id="O2" value="44.9" spread="23.78"/>
                    <measurement group_id="O3" value="41.6" spread="23.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Assessment of Pain Week 52 (EOS)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="94"/>
                    <count group_id="O2" value="91"/>
                    <count group_id="O3" value="91"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.2" spread="24.34"/>
                    <measurement group_id="O2" value="43.2" spread="24.42"/>
                    <measurement group_id="O3" value="44.5" spread="26.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 52 (EOS) Participants Pain Assessment. Least square means and confidence intervals were estimated from an ANCOVA model containing treatment group as a factor and baseline value as a covariate. Change from Study Day 1 (Baseline).</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.7322</p_value>
            <method>ANCOVA</method>
            <param_type>LS Means Difference</param_type>
            <param_value>-1.23</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.592</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.0302</ci_lower_limit>
            <ci_upper_limit>5.841</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 52 (EOS) Participants Pain Assessment. Least square means and confidence intervals were estimated from an ANCOVA model containing treatment group as a factor and baseline value as a covariate. Change from Study Day 1 (Baseline).</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.5418</p_value>
            <method>ANCOVA</method>
            <param_type>LS Means Difference</param_type>
            <param_value>-2.21</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.623</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.347</ci_lower_limit>
            <ci_upper_limit>4.920</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 52 (EOS) Participants Pain Assessment. Least square means and confidence intervals were estimated from an ANCOVA model containing treatment group as a factor and baseline value as a covariate. Change from Study Day 1 (Baseline).</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.7869</p_value>
            <method>ANCOVA</method>
            <param_type>LS Means Difference</param_type>
            <param_value>-0.98</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.633</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.136</ci_lower_limit>
            <ci_upper_limit>6.169</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Individual Components of the ACR Improvement Criteria on Day 1 and at Weeks 8, 16, 24, 36 and 52: Participants Global Assessment of Disease Activity (Assessed on 1 to 100 mm VAS)</title>
        <description>Efficacy endpoint: Individual Components of the ACR Improvement Criteria on Day 1 and at Weeks 8, 16, 24, 36 and 52: Participants global assessment of disease activity (assessed on 1 to 100 mm visual analogue scale [VAS]). Patients rate how their Rheumatoid Arthritis has affected them, where 0 = very well and 100 = very poor.</description>
        <time_frame>Baseline and Weeks 8, 16, 24, 36 and 52 (EOS)</time_frame>
        <population>Full Analysis Set (analyses are reported in terms of the arm that the patient was initially randomised into. In the Rituxan arm only, patients eligible for treatment in Part B underwent a second randomisation to receive either Rituxan or SAIT101 and are reported in the Rituxan arm according to their initial randomisation).</population>
        <group_list>
          <group group_id="O1">
            <title>SAIT101</title>
            <description>1000 mg intravenous (iv) SAIT101 on Day 1 and 15 (Part A). 1000 mg iv SAIT101 on week 24 and 26 (Part B) for eligible participants,</description>
          </group>
          <group group_id="O2">
            <title>MabThera</title>
            <description>1000 mg iv MabThera on Day 1 and 15 (Part A). 1000 mg iv MabThera on week 24 and 26 (Part B) for eligible participants.</description>
          </group>
          <group group_id="O3">
            <title>Rituxan</title>
            <description>1000 mg iv of Rituxan on Day 1 and 15 (Part A). 1000 mg iv of Rituxan on week 24 and 26 (Part B) for eligible participants</description>
          </group>
        </group_list>
        <measure>
          <title>Individual Components of the ACR Improvement Criteria on Day 1 and at Weeks 8, 16, 24, 36 and 52: Participants Global Assessment of Disease Activity (Assessed on 1 to 100 mm VAS)</title>
          <description>Efficacy endpoint: Individual Components of the ACR Improvement Criteria on Day 1 and at Weeks 8, 16, 24, 36 and 52: Participants global assessment of disease activity (assessed on 1 to 100 mm visual analogue scale [VAS]). Patients rate how their Rheumatoid Arthritis has affected them, where 0 = very well and 100 = very poor.</description>
          <population>Full Analysis Set (analyses are reported in terms of the arm that the patient was initially randomised into. In the Rituxan arm only, patients eligible for treatment in Part B underwent a second randomisation to receive either Rituxan or SAIT101 and are reported in the Rituxan arm according to their initial randomisation).</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="98"/>
                <count group_id="O3" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Disease activity Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="97"/>
                    <count group_id="O2" value="97"/>
                    <count group_id="O3" value="97"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.9" spread="15.87"/>
                    <measurement group_id="O2" value="67.6" spread="17.53"/>
                    <measurement group_id="O3" value="70.8" spread="17.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease activity Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="95"/>
                    <count group_id="O2" value="94"/>
                    <count group_id="O3" value="93"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.9" spread="22.57"/>
                    <measurement group_id="O2" value="49.1" spread="22.98"/>
                    <measurement group_id="O3" value="48.5" spread="22.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease activity Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="94"/>
                    <count group_id="O2" value="93"/>
                    <count group_id="O3" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.9" spread="21.47"/>
                    <measurement group_id="O2" value="44.4" spread="21.63"/>
                    <measurement group_id="O3" value="44.2" spread="22.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease activity Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="92"/>
                    <count group_id="O2" value="88"/>
                    <count group_id="O3" value="86"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.8" spread="23.16"/>
                    <measurement group_id="O2" value="51.1" spread="20.49"/>
                    <measurement group_id="O3" value="52.3" spread="21.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease activity Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="90"/>
                    <count group_id="O2" value="82"/>
                    <count group_id="O3" value="85"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.7" spread="22.63"/>
                    <measurement group_id="O2" value="42.7" spread="22.54"/>
                    <measurement group_id="O3" value="42.5" spread="23.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease activity Week 52 (EOS)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="95"/>
                    <count group_id="O2" value="91"/>
                    <count group_id="O3" value="91"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.4" spread="23.02"/>
                    <measurement group_id="O2" value="42.4" spread="24.10"/>
                    <measurement group_id="O3" value="43.1" spread="23.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 52 (EOS) Participants Disease Activity Assessment. Least square means and confidence intervals were estimated from an ANCOVA model containing treatment group as a factor and baseline value as a covariate. Change from Study Day 1 (Baseline)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.7097</p_value>
            <method>ANCOVA</method>
            <param_type>LS Means Difference</param_type>
            <param_value>-1.28</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.443</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.062</ci_lower_limit>
            <ci_upper_limit>5.496</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 52 (EOS) Participants Disease Activity Assessment. Least square means and confidence intervals were estimated from an ANCOVA model containing treatment group as a factor and baseline value as a covariate. Change from Study Day 1 (Baseline)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.6683</p_value>
            <method>ANCOVA</method>
            <param_type>LS Means Difference</param_type>
            <param_value>-1.48</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.453</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.280</ci_lower_limit>
            <ci_upper_limit>5.317</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 52 (EOS) Participants Disease Activity Assessment. Least square means and confidence intervals were estimated from an ANCOVA model containing treatment group as a factor and baseline value as a covariate. Change from Study Day 1 (Baseline)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.9548</p_value>
            <method>ANCOVA</method>
            <param_type>LS Means Difference</param_type>
            <param_value>-0.20</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.494</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.078</ci_lower_limit>
            <ci_upper_limit>6.682</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Individual Components of the ACR Improvement Criteria on Day 1 and at Weeks 8, 16, 24, 36 and 52: Participants Assessment of Disability (Health Assessment Questionnaire-Disability Index [HAQ-DI])</title>
        <description>the Health Assessment Questionnaire-Disability Index (HAQ-DI) contains 20 questions split into 8 categories (dressing &amp; grooming, arising, eating, walking, hygiene, reach, grip &amp; activities). Scores were: 0 = Without ANY Difficulty; 1 = With SOME Difficulty; 2 = With MUCH Difficulty; 3 = UNABLE to Do. Total scores were calculated as the summed category scores divided by the number of categories.
Total HAQ-DI scores are presented which range from 0 to 3. Higher scores represent a worse outcome. Scores of 0 to 1 represent mild to moderate difficulty, 1 to 2 moderate disability, and 2 to 3 severe to very severe disability.</description>
        <time_frame>Baseline and Weeks 8, 16, 24, 36 and 52 (EOS)</time_frame>
        <population>Full Analysis Set (analyses are reported in terms of the arm that the patient was initially randomised into. In the Rituxan arm only, patients eligible for treatment in Part B underwent a second randomisation to receive either Rituxan or SAIT101 and are reported in the Rituxan arm according to their initial randomisation).</population>
        <group_list>
          <group group_id="O1">
            <title>SAIT101</title>
            <description>1000 mg intravenous (iv) SAIT101 on Day 1 and 15 (Part A). 1000 mg iv SAIT101 on week 24 and 26 (Part B) for eligible participants,</description>
          </group>
          <group group_id="O2">
            <title>MabThera</title>
            <description>1000 mg iv MabThera on Day 1 and 15 (Part A). 1000 mg iv MabThera on week 24 and 26 (Part B) for eligible participants.</description>
          </group>
          <group group_id="O3">
            <title>Rituxan</title>
            <description>1000 mg iv of Rituxan on Day 1 and 15 (Part A). 1000 mg iv of Rituxan on week 24 and 26 (Part B) for eligible participants</description>
          </group>
        </group_list>
        <measure>
          <title>Individual Components of the ACR Improvement Criteria on Day 1 and at Weeks 8, 16, 24, 36 and 52: Participants Assessment of Disability (Health Assessment Questionnaire-Disability Index [HAQ-DI])</title>
          <description>the Health Assessment Questionnaire-Disability Index (HAQ-DI) contains 20 questions split into 8 categories (dressing &amp; grooming, arising, eating, walking, hygiene, reach, grip &amp; activities). Scores were: 0 = Without ANY Difficulty; 1 = With SOME Difficulty; 2 = With MUCH Difficulty; 3 = UNABLE to Do. Total scores were calculated as the summed category scores divided by the number of categories.
Total HAQ-DI scores are presented which range from 0 to 3. Higher scores represent a worse outcome. Scores of 0 to 1 represent mild to moderate difficulty, 1 to 2 moderate disability, and 2 to 3 severe to very severe disability.</description>
          <population>Full Analysis Set (analyses are reported in terms of the arm that the patient was initially randomised into. In the Rituxan arm only, patients eligible for treatment in Part B underwent a second randomisation to receive either Rituxan or SAIT101 and are reported in the Rituxan arm according to their initial randomisation).</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="98"/>
                <count group_id="O3" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HAQ-DI Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="98"/>
                    <count group_id="O2" value="98"/>
                    <count group_id="O3" value="97"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.610" spread="0.5728"/>
                    <measurement group_id="O2" value="1.605" spread="0.6567"/>
                    <measurement group_id="O3" value="1.585" spread="0.6421"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HAQ-DI Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="95"/>
                    <count group_id="O2" value="94"/>
                    <count group_id="O3" value="93"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.168" spread="0.6318"/>
                    <measurement group_id="O2" value="1.314" spread="0.6919"/>
                    <measurement group_id="O3" value="1.176" spread="0.6398"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HAQ-DI Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="94"/>
                    <count group_id="O2" value="93"/>
                    <count group_id="O3" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.129" spread="0.5775"/>
                    <measurement group_id="O2" value="1.246" spread="0.6394"/>
                    <measurement group_id="O3" value="1.152" spread="0.6668"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HAQ-DI Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="92"/>
                    <count group_id="O2" value="88"/>
                    <count group_id="O3" value="86"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.209" spread="0.6071"/>
                    <measurement group_id="O2" value="1.335" spread="0.6381"/>
                    <measurement group_id="O3" value="1.294" spread="0.6594"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HAQ-DI Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="90"/>
                    <count group_id="O2" value="83"/>
                    <count group_id="O3" value="84"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.994" spread="0.6220"/>
                    <measurement group_id="O2" value="1.182" spread="0.6883"/>
                    <measurement group_id="O3" value="1.061" spread="0.6247"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HAQ-DI Week 52 (EOS)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="94"/>
                    <count group_id="O2" value="91"/>
                    <count group_id="O3" value="91"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.027" spread="0.6208"/>
                    <measurement group_id="O2" value="1.207" spread="0.7025"/>
                    <measurement group_id="O3" value="1.190" spread="0.7116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 52 (EOS) HAQ-DI (0-3). Least square means and confidence intervals were estimated from an ANCOVA model containing treatment group as a factor and baseline value as a covariate. Change from Study Day 1 (Baseline).</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0505</p_value>
            <method>ANCOVA</method>
            <param_type>LS Means Difference</param_type>
            <param_value>-0.14</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.086</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.339</ci_lower_limit>
            <ci_upper_limit>0.000</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 52 (EOS) HAQ-DI (0-3). Least square means and confidence intervals were estimated from an ANCOVA model containing treatment group as a factor and baseline value as a covariate. Change from Study Day 1 (Baseline).</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.1141</p_value>
            <method>ANCOVA</method>
            <param_type>LS Means Difference</param_type>
            <param_value>-0.14</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.086</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.307</ci_lower_limit>
            <ci_upper_limit>0.033</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 52 (EOS) HAQ-DI )0-3). Least square means and confidence intervals were estimated from an ANCOVA model containing treatment group as a factor and baseline value as a covariate. Change from Study Day 1 (Baseline).</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.7111</p_value>
            <method>ANCOVA</method>
            <param_type>LS Means Difference</param_type>
            <param_value>0.03</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.087</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.139</ci_lower_limit>
            <ci_upper_limit>0.204</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Individual Components of the ACR Improvement Criteria on Day 1 and at Weeks 8, 16, 24, 36 and 52: C-reactive Protein (CRP) Level</title>
        <description>C-reactive protein (CRP) level (Mg/L). CRP is a marker for inflammation. a normal reading is &lt;3 Mg/L. Higher values indicate disease related inflammation and increased cardiovascular risk.
CRP levels between 3 Mg/L and 10 Mg/L are mildly elevated. Levels between 10 Mg/L and 100 Mg/L are moderately elevated and CRP levels above 100 Mg/L are severely elevated.</description>
        <time_frame>Baseline and Weeks 8, 16, 24, 36 and 52 (EOS)</time_frame>
        <population>Full Analysis Set (analyses are reported in terms of the arm that the patient was initially randomised into. In the Rituxan arm only, patients eligible for treatment in Part B underwent a second randomisation to receive either Rituxan or SAIT101 and are reported in the Rituxan arm according to their initial randomisation).</population>
        <group_list>
          <group group_id="O1">
            <title>SAIT101</title>
            <description>1000 mg intravenous (iv) SAIT101 on Day 1 and 15 (Part A). 1000 mg iv SAIT101 on week 24 and 26 (Part B) for eligible participants,</description>
          </group>
          <group group_id="O2">
            <title>MabThera</title>
            <description>1000 mg iv MabThera on Day 1 and 15 (Part A). 1000 mg iv MabThera on week 24 and 26 (Part B) for eligible participants.</description>
          </group>
          <group group_id="O3">
            <title>Rituxan</title>
            <description>1000 mg iv of Rituxan on Day 1 and 15 (Part A). 1000 mg iv of Rituxan on week 24 and 26 (Part B) for eligible participants</description>
          </group>
        </group_list>
        <measure>
          <title>Individual Components of the ACR Improvement Criteria on Day 1 and at Weeks 8, 16, 24, 36 and 52: C-reactive Protein (CRP) Level</title>
          <description>C-reactive protein (CRP) level (Mg/L). CRP is a marker for inflammation. a normal reading is &lt;3 Mg/L. Higher values indicate disease related inflammation and increased cardiovascular risk.
CRP levels between 3 Mg/L and 10 Mg/L are mildly elevated. Levels between 10 Mg/L and 100 Mg/L are moderately elevated and CRP levels above 100 Mg/L are severely elevated.</description>
          <population>Full Analysis Set (analyses are reported in terms of the arm that the patient was initially randomised into. In the Rituxan arm only, patients eligible for treatment in Part B underwent a second randomisation to receive either Rituxan or SAIT101 and are reported in the Rituxan arm according to their initial randomisation).</population>
          <units>Mg/L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="98"/>
                <count group_id="O3" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CRP Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="98"/>
                    <count group_id="O2" value="98"/>
                    <count group_id="O3" value="98"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.5" spread="28.99"/>
                    <measurement group_id="O2" value="15.3" spread="20.63"/>
                    <measurement group_id="O3" value="16.2" spread="17.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CRP Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="93"/>
                    <count group_id="O2" value="93"/>
                    <count group_id="O3" value="93"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5" spread="15.78"/>
                    <measurement group_id="O2" value="12.3" spread="20.29"/>
                    <measurement group_id="O3" value="10.4" spread="12.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CRP Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="93"/>
                    <count group_id="O2" value="93"/>
                    <count group_id="O3" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.5" spread="11.78"/>
                    <measurement group_id="O2" value="7.2" spread="9.02"/>
                    <measurement group_id="O3" value="7.3" spread="6.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CRP Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="91"/>
                    <count group_id="O2" value="88"/>
                    <count group_id="O3" value="85"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.5" spread="14.54"/>
                    <measurement group_id="O2" value="8.3" spread="14.40"/>
                    <measurement group_id="O3" value="7.9" spread="10.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CRP Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="90"/>
                    <count group_id="O2" value="83"/>
                    <count group_id="O3" value="85"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0" spread="20.33"/>
                    <measurement group_id="O2" value="7.0" spread="10.38"/>
                    <measurement group_id="O3" value="7.1" spread="9.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CRP Week 52 (EOS)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="92"/>
                    <count group_id="O2" value="88"/>
                    <count group_id="O3" value="88"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.8" spread="14.14"/>
                    <measurement group_id="O2" value="9.1" spread="14.93"/>
                    <measurement group_id="O3" value="7.4" spread="11.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 52 (EOS) CRP. Least square means and confidence intervals were estimated from an ANCOVA model containing treatment group as a factor and baseline value as a covariate. Change from Study Day 1 (Baseline).</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.8183</p_value>
            <method>ANCOVA</method>
            <param_type>LS Means Difference</param_type>
            <param_value>-0.43</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.871</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.113</ci_lower_limit>
            <ci_upper_limit>3.253</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 52 (EOS) CRP. Least square means and confidence intervals were estimated from an ANCOVA model containing treatment group as a factor and baseline value as a covariate. Change from Study Day 1 (Baseline).</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.4186</p_value>
            <method>ANCOVA</method>
            <param_type>LS Means Difference</param_type>
            <param_value>1.51</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.868</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.164</ci_lower_limit>
            <ci_upper_limit>5.191</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 52 (EOS) CRP. Least square means and confidence intervals were estimated from an ANCOVA model containing treatment group as a factor and baseline value as a covariate. Change from Study Day 1 (Baseline).</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.3035</p_value>
            <method>ANCOVA</method>
            <param_type>LS Means Difference</param_type>
            <param_value>1.94</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.885</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.768</ci_lower_limit>
            <ci_upper_limit>5.655</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline DAS28-erythrocyte Sedimentation Rate (ESR) at Weeks 8, 16, 24, 36 and 52</title>
        <description>Disease Activity Score 28- Erythrocyte Sedimentation Rate (DAS28-ESR) consisted of tender joint counts (TJC), swollen joint counts (SJC) &amp; erythrocyte sedimentation rate (ESR). The formula is: [0.56*SQRT(tender 28 joint count)+0.28*SQRT(swollen 28 joint count)+0.7*ln(ESR)]+0.014*patient global health assessment.
Total DAS28-ESR scores are presented. Total scores range from 2 (minimum) to 10 (maximum). A lower score represents a better patient outcome. A DAS28-ESR of greater than 5.1 implies active disease, less than 3.2 low disease activity, and less than 2.6 remission.</description>
        <time_frame>Baseline and Weeks 8, 16, 24, 36 and 52 (EOS)</time_frame>
        <population>Full Analysis Set (analyses are reported in terms of the arm that the patient was initially randomised into. In the Rituxan arm only, patients eligible for treatment in Part B underwent a second randomisation to receive either Rituxan or SAIT101 and are reported in the Rituxan arm according to their initial randomisation).</population>
        <group_list>
          <group group_id="O1">
            <title>SAIT101</title>
            <description>1000 mg intravenous (iv) SAIT101 on Day 1 and 15 (Part A). 1000 mg iv SAIT101 on week 24 and 26 (Part B) for eligible participants,</description>
          </group>
          <group group_id="O2">
            <title>MabThera</title>
            <description>1000 mg iv MabThera on Day 1 and 15 (Part A). 1000 mg iv MabThera on week 24 and 26 (Part B) for eligible participants.</description>
          </group>
          <group group_id="O3">
            <title>Rituxan</title>
            <description>1000 mg iv of Rituxan on Day 1 and 15 (Part A). 1000 mg iv of Rituxan on week 24 and 26 (Part B) for eligible participants</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline DAS28-erythrocyte Sedimentation Rate (ESR) at Weeks 8, 16, 24, 36 and 52</title>
          <description>Disease Activity Score 28- Erythrocyte Sedimentation Rate (DAS28-ESR) consisted of tender joint counts (TJC), swollen joint counts (SJC) &amp; erythrocyte sedimentation rate (ESR). The formula is: [0.56*SQRT(tender 28 joint count)+0.28*SQRT(swollen 28 joint count)+0.7*ln(ESR)]+0.014*patient global health assessment.
Total DAS28-ESR scores are presented. Total scores range from 2 (minimum) to 10 (maximum). A lower score represents a better patient outcome. A DAS28-ESR of greater than 5.1 implies active disease, less than 3.2 low disease activity, and less than 2.6 remission.</description>
          <population>Full Analysis Set (analyses are reported in terms of the arm that the patient was initially randomised into. In the Rituxan arm only, patients eligible for treatment in Part B underwent a second randomisation to receive either Rituxan or SAIT101 and are reported in the Rituxan arm according to their initial randomisation).</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="98"/>
                <count group_id="O3" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>DAS28-ESR Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="96"/>
                    <count group_id="O2" value="96"/>
                    <count group_id="O3" value="96"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.537" spread="0.8440"/>
                    <measurement group_id="O2" value="6.533" spread=".07810"/>
                    <measurement group_id="O3" value="6.480" spread="0.7577"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-ESR Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="94"/>
                    <count group_id="O2" value="92"/>
                    <count group_id="O3" value="93"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.330" spread="1.0649"/>
                    <measurement group_id="O2" value="5.315" spread="1.2478"/>
                    <measurement group_id="O3" value="5.235" spread="1.2578"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-ESR Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="94"/>
                    <count group_id="O2" value="92"/>
                    <count group_id="O3" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.861" spread="1.1876"/>
                    <measurement group_id="O2" value="5.059" spread="1.1682"/>
                    <measurement group_id="O3" value="4.957" spread="1.1802"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-ESR Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="92"/>
                    <count group_id="O2" value="87"/>
                    <count group_id="O3" value="85"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.216" spread="1.2510"/>
                    <measurement group_id="O2" value="5.410" spread="1.2344"/>
                    <measurement group_id="O3" value="5.432" spread="1.1891"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-ESR Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="90"/>
                    <count group_id="O2" value="80"/>
                    <count group_id="O3" value="80"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.319" spread="1.2798"/>
                    <measurement group_id="O2" value="4.689" spread="1.0077"/>
                    <measurement group_id="O3" value="4.499" spread="1.1980"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-ESR Week 52 (EOS)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="92"/>
                    <count group_id="O2" value="86"/>
                    <count group_id="O3" value="82"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.435" spread="1.4375"/>
                    <measurement group_id="O2" value="4.485" spread="1.4390"/>
                    <measurement group_id="O3" value="4.391" spread="1.3947"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 52 ( EOS) Least square means and confidence intervals were estimated from an ANCOVA model containing treatment group as a factor and baseline DAS28-ESR value as a covariate. ANCOVA model contains treatment group only.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.9249</p_value>
            <method>ANCOVA</method>
            <param_type>LS Means Difference</param_type>
            <param_value>0.02</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.200</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.375</ci_lower_limit>
            <ci_upper_limit>0.413</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 52 ( EOS) Least square means and confidence intervals were estimated from an ANCOVA model containing treatment group as a factor and baseline DAS28-ESR value as a covariate. ANCOVA model contains treatment group only.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.05</p_value>
            <method>ANCOVA</method>
            <param_type>LS Measn Difference</param_type>
            <param_value>0.05</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.201</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.351</ci_lower_limit>
            <ci_upper_limit>0.442</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 52 ( EOS) Least square means and confidence intervals were estimated from an ANCOVA model containing treatment group as a factor and baseline DAS28-ESR value as a covariate. ANCOVA model contains treatment group only.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.8962</p_value>
            <method>ANCOVA</method>
            <param_type>LS Means Diference</param_type>
            <param_value>0.03</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.205</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.376</ci_lower_limit>
            <ci_upper_limit>0.430</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With a Major Clinical Response (Continuous ACR70) for at Least 24 Weeks</title>
        <description>Efficacy endpoint: number of participants with a major clinical response defined as a continuous ACR70 from Baseline (Day 1) for at least 24 weeks.
ACR70 is a measure based on American College of Rheumatology criteria of at least a 70% improvement in the number of tender and swollen joints, and a 70% improvement in at least 3 of the following: the patient's global assessment of disease status; the patient's assessment of pain; the patient's assessment of function measured using the Stanford Health Assessment Questionnaire the physician's global assessment of disease status; serum C-reactive protein levels.</description>
        <time_frame>Baseline and Weeks 8, 16, 24, 36 and 52 (EOS)</time_frame>
        <population>Full Analysis Set (analyses are reported in terms of the arm that the patient was initially randomised into. In the Rituxan arm only, patients eligible for treatment in Part B underwent a second randomisation to receive either Rituxan or SAIT101 and are reported in the Rituxan arm according to their initial randomisation).</population>
        <group_list>
          <group group_id="O1">
            <title>SAIT101</title>
            <description>1000 mg intravenous (iv) SAIT101 on Day 1 and 15 (Part A). 1000 mg iv SAIT101 on week 24 and 26 (Part B) for eligible participants,</description>
          </group>
          <group group_id="O2">
            <title>MabThera</title>
            <description>1000 mg iv MabThera on Day 1 and 15 (Part A). 1000 mg iv MabThera on week 24 and 26 (Part B) for eligible participants.</description>
          </group>
          <group group_id="O3">
            <title>Rituxan</title>
            <description>1000 mg iv of Rituxan on Day 1 and 15 (Part A). 1000 mg iv of Rituxan on week 24 and 26 (Part B) for eligible participants</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Major Clinical Response (Continuous ACR70) for at Least 24 Weeks</title>
          <description>Efficacy endpoint: number of participants with a major clinical response defined as a continuous ACR70 from Baseline (Day 1) for at least 24 weeks.
ACR70 is a measure based on American College of Rheumatology criteria of at least a 70% improvement in the number of tender and swollen joints, and a 70% improvement in at least 3 of the following: the patient's global assessment of disease status; the patient's assessment of pain; the patient's assessment of function measured using the Stanford Health Assessment Questionnaire the physician's global assessment of disease status; serum C-reactive protein levels.</description>
          <population>Full Analysis Set (analyses are reported in terms of the arm that the patient was initially randomised into. In the Rituxan arm only, patients eligible for treatment in Part B underwent a second randomisation to receive either Rituxan or SAIT101 and are reported in the Rituxan arm according to their initial randomisation).</population>
          <units>participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="98"/>
                <count group_id="O3" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Major Clinical Response Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="92"/>
                    <count group_id="O2" value="86"/>
                    <count group_id="O3" value="85"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="0.19" upper_limit="5.90"/>
                    <measurement group_id="O2" value="0" lower_limit="0.00" upper_limit="4.28"/>
                    <measurement group_id="O3" value="0" lower_limit="0.00" upper_limit="4.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Major Clinical Response Week 52 (EOS)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="89"/>
                    <count group_id="O2" value="81"/>
                    <count group_id="O3" value="80"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="0.62" upper_limit="7.83"/>
                    <measurement group_id="O2" value="0" lower_limit="0.00" upper_limit="4.53"/>
                    <measurement group_id="O3" value="1" lower_limit="0.22" upper_limit="6.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 52 (EOS) Major Clinical Response. The 95% CIs for major clinical response rate and treatment difference were derived using the Wilson Score method. The adjusted difference and its 95% CI are from a logistic regression model containing treatment group as a factor and baseline DAS28-CRP as a covariate.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference (%)</param_type>
            <param_value>2.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.57</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.56</ci_lower_limit>
            <ci_upper_limit>7.83</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 52 (EOS) Major Clinical Response. The 95% CIs for major clinical response rate and treatment difference were derived using the Wilson Score method. The adjusted difference and its 95% CI are from a logistic regression model containing treatment group as a factor and baseline DAS28-CRP as a covariate.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference (%)</param_type>
            <param_value>1.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.0</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.74</ci_lower_limit>
            <ci_upper_limit>6.67</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 52 (EOS) Major Clinical Response. The 95% CIs for major clinical response rate and treatment difference were derived using the Wilson Score method. The adjusted difference and its 95% CI are from a logistic regression model containing treatment group as a factor and baseline DAS28-CRP as a covariate.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference (%)</param_type>
            <param_value>-1.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.24</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.75</ci_lower_limit>
            <ci_upper_limit>3.39</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With a Clinical Remission Response (CRR) at Weeks 8, 16, 24, 36 and 52</title>
        <description>Number if Participants with a Clinical Remission Response (CRR) defined by the Simplified Disease Activity Index (SDAI) &lt;3.3 at weeks 8, 16, 24, 36 and 52 (EOS).</description>
        <time_frame>Baseline and Weeks 8, 16, 24, 36 and 52 (EOS)</time_frame>
        <population>Full Analysis Set (analyses are reported in terms of the arm that the patient was initially randomised into. In the Rituxan arm only, patients eligible for treatment in Part B underwent a second randomisation to receive either Rituxan or SAIT101 and are reported in the Rituxan arm according to their initial randomisation).</population>
        <group_list>
          <group group_id="O1">
            <title>SAIT101</title>
            <description>1000 mg intravenous (iv) SAIT101 on Day 1 and 15 (Part A). 1000 mg iv SAIT101 on week 24 and 26 (Part B) for eligible participants,</description>
          </group>
          <group group_id="O2">
            <title>MabThera</title>
            <description>1000 mg iv MabThera on Day 1 and 15 (Part A). 1000 mg iv MabThera on week 24 and 26 (Part B) for eligible participants.</description>
          </group>
          <group group_id="O3">
            <title>Rituxan</title>
            <description>1000 mg iv of Rituxan on Day 1 and 15 (Part A). 1000 mg iv of Rituxan on week 24 and 26 (Part B) for eligible participants</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Clinical Remission Response (CRR) at Weeks 8, 16, 24, 36 and 52</title>
          <description>Number if Participants with a Clinical Remission Response (CRR) defined by the Simplified Disease Activity Index (SDAI) &lt;3.3 at weeks 8, 16, 24, 36 and 52 (EOS).</description>
          <population>Full Analysis Set (analyses are reported in terms of the arm that the patient was initially randomised into. In the Rituxan arm only, patients eligible for treatment in Part B underwent a second randomisation to receive either Rituxan or SAIT101 and are reported in the Rituxan arm according to their initial randomisation).</population>
          <units>participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="98"/>
                <count group_id="O3" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CRR Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="93"/>
                    <count group_id="O2" value="92"/>
                    <count group_id="O3" value="91"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0.00" upper_limit="3.97"/>
                    <measurement group_id="O2" value="0" lower_limit="0.00" upper_limit="4.01"/>
                    <measurement group_id="O3" value="0" lower_limit="0.00" upper_limit="4.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CRR Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="92"/>
                    <count group_id="O2" value="93"/>
                    <count group_id="O3" value="91"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0.00" upper_limit="4.01"/>
                    <measurement group_id="O2" value="1" lower_limit="0.19" upper_limit="5.84"/>
                    <measurement group_id="O3" value="0" lower_limit="0.00" upper_limit="4.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CRR Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="90"/>
                    <count group_id="O2" value="87"/>
                    <count group_id="O3" value="84"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0.00" upper_limit="4.09"/>
                    <measurement group_id="O2" value="1" lower_limit="0.20" upper_limit="6.23"/>
                    <measurement group_id="O3" value="0" lower_limit="0.00" upper_limit="4.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CRR Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="90"/>
                    <count group_id="O2" value="82"/>
                    <count group_id="O3" value="83"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="0.61" upper_limit="7.74"/>
                    <measurement group_id="O2" value="0" lower_limit="0.00" upper_limit="4.48"/>
                    <measurement group_id="O3" value="1" lower_limit="0.21" upper_limit="6.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CRR Week 52 (EOS)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="92"/>
                    <count group_id="O2" value="88"/>
                    <count group_id="O3" value="86"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="0.19" upper_limit="5.90"/>
                    <measurement group_id="O2" value="2" lower_limit="0.63" upper_limit="7.91"/>
                    <measurement group_id="O3" value="2" lower_limit="0.64" upper_limit="8.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 52 (EOS). Clinical remission is defined as score of Simplified Disease Activity Index (SDAI) smaller than 3.3. The 95% CIs for clinical remission rate and treatment difference were derived using the Wilson Score method. The adjusted difference and its 95% CI are from a logistic regression model containing treatment group as a factor and baseline DAS28-CRP as a covariate.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference (%)</param_type>
            <param_value>-1.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.92</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.9</ci_lower_limit>
            <ci_upper_limit>3.90</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 52 (EOS). Clinical remission is defined as score of Simplified Disease Activity Index (SDAI) smaller than 3.3. The 95% CIs for clinical remission rate and treatment difference were derived using the Wilson Score method. The adjusted difference and its 95% CI are from a logistic regression model containing treatment group as a factor and baseline DAS28-CRP as a covariate.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference (%)</param_type>
            <param_value>-1.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.95</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.07</ci_lower_limit>
            <ci_upper_limit>3.86</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 52 (EOS). Clinical remission is defined as score of Simplified Disease Activity Index (SDAI) smaller than 3.3. The 95% CIs for clinical remission rate and treatment difference were derived using the Wilson Score method. The adjusted difference and its 95% CI are from a logistic regression model containing treatment group as a factor and baseline DAS28-CRP as a covariate.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Differnce (%)</param_type>
            <param_value>-0.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.27</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.05</ci_lower_limit>
            <ci_upper_limit>5.83</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Participants With European League Against Rheumatism (EULAR) Response at Weeks 8, 16, 24 36 and 52</title>
        <description>Efficacy endpoint: Proportion of participants with European League Against Rheumatism (EULAR) response (defined as good response, moderate response or no response) at weeks 8, 16, 24 36 and 52 (EOS). EULAR (European League Against Rheumatism) response was classified using the individual amount of change in the DAS28-CRP score. The DAS28-CRP was classified into 3 categories: low disease activity (&lt;= 3.2), moderate disease activity (&gt; 3.2 and &lt;= 5.1) and high disease activity (&gt; 5.1). Good response was defined as &gt;1.2 improvement in the DAS28-CRP from baseline with low disease activity.</description>
        <time_frame>Baseline and Weeks 8, 16, 24, 36 and 52 (EOS)</time_frame>
        <population>Full Analysis Set (analyses are reported in terms of the arm that the patient was initially randomised into. In the Rituxan arm only, patients eligible for treatment in Part B underwent a second randomisation to receive either Rituxan or SAIT101 and are reported in the Rituxan arm according to their initial randomisation).</population>
        <group_list>
          <group group_id="O1">
            <title>SAIT101</title>
            <description>1000 mg intravenous (iv) SAIT101 on Day 1 and 15 (Part A). 1000 mg iv SAIT101 on week 24 and 26 (Part B) for eligible participants,</description>
          </group>
          <group group_id="O2">
            <title>MabThera</title>
            <description>1000 mg iv MabThera on Day 1 and 15 (Part A). 1000 mg iv MabThera on week 24 and 26 (Part B) for eligible participants.</description>
          </group>
          <group group_id="O3">
            <title>Rituxan</title>
            <description>1000 mg iv of Rituxan on Day 1 and 15 (Part A). 1000 mg iv of Rituxan on week 24 and 26 (Part B) for eligible participants</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Participants With European League Against Rheumatism (EULAR) Response at Weeks 8, 16, 24 36 and 52</title>
          <description>Efficacy endpoint: Proportion of participants with European League Against Rheumatism (EULAR) response (defined as good response, moderate response or no response) at weeks 8, 16, 24 36 and 52 (EOS). EULAR (European League Against Rheumatism) response was classified using the individual amount of change in the DAS28-CRP score. The DAS28-CRP was classified into 3 categories: low disease activity (&lt;= 3.2), moderate disease activity (&gt; 3.2 and &lt;= 5.1) and high disease activity (&gt; 5.1). Good response was defined as &gt;1.2 improvement in the DAS28-CRP from baseline with low disease activity.</description>
          <population>Full Analysis Set (analyses are reported in terms of the arm that the patient was initially randomised into. In the Rituxan arm only, patients eligible for treatment in Part B underwent a second randomisation to receive either Rituxan or SAIT101 and are reported in the Rituxan arm according to their initial randomisation).</population>
          <units>participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="98"/>
                <count group_id="O3" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 8 Good</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="93"/>
                    <count group_id="O2" value="92"/>
                    <count group_id="O3" value="93"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12" lower_limit="7.54" upper_limit="21.21"/>
                    <measurement group_id="O2" value="14" lower_limit="9.29" upper_limit="23.94"/>
                    <measurement group_id="O3" value="12" lower_limit="7.54" upper_limit="21.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 Good or Moderate</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="93"/>
                    <count group_id="O2" value="92"/>
                    <count group_id="O3" value="93"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30" lower_limit="23.62" upper_limit="42.30"/>
                    <measurement group_id="O2" value="33" lower_limit="26.82" upper_limit="46.05"/>
                    <measurement group_id="O3" value="33" lower_limit="26.51" upper_limit="45.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 Good</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="93"/>
                    <count group_id="O2" value="92"/>
                    <count group_id="O3" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20" lower_limit="14.38" upper_limit="30.90"/>
                    <measurement group_id="O2" value="12" lower_limit="7.62" upper_limit="21.43"/>
                    <measurement group_id="O3" value="13" lower_limit="8.45" upper_limit="22.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 Good or Moderate</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="93"/>
                    <count group_id="O2" value="92"/>
                    <count group_id="O3" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44" lower_limit="37.47" upper_limit="57.36"/>
                    <measurement group_id="O2" value="42" lower_limit="35.85" upper_limit="55.80"/>
                    <measurement group_id="O3" value="33" lower_limit="26.82" upper_limit="46.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 Good</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="91"/>
                    <count group_id="O2" value="87"/>
                    <count group_id="O3" value="85"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12" lower_limit="7.71" upper_limit="21.65"/>
                    <measurement group_id="O2" value="7" lower_limit="3.95" upper_limit="15.69"/>
                    <measurement group_id="O3" value="7" lower_limit="4.05" upper_limit="16.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 Good or Moderate</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="91"/>
                    <count group_id="O2" value="87"/>
                    <count group_id="O3" value="85"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30" lower_limit="24.17" upper_limit="43.14"/>
                    <measurement group_id="O2" value="26" lower_limit="21.28" upper_limit="40.19"/>
                    <measurement group_id="O3" value="23" lower_limit="18.76" upper_limit="37.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36 Good</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="90"/>
                    <count group_id="O2" value="82"/>
                    <count group_id="O3" value="84"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27" lower_limit="21.51" upper_limit="40.13"/>
                    <measurement group_id="O2" value="15" lower_limit="11.41" upper_limit="28.01"/>
                    <measurement group_id="O3" value="27" lower_limit="23.13" upper_limit="42.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36 Good or Moderate</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="90"/>
                    <count group_id="O2" value="82"/>
                    <count group_id="O3" value="84"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58" lower_limit="54.15" upper_limit="73.56"/>
                    <measurement group_id="O2" value="50" lower_limit="50.00" upper_limit="70.82"/>
                    <measurement group_id="O3" value="54" lower_limit="53.62" upper_limit="73.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (EOS) Good</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="92"/>
                    <count group_id="O2" value="87"/>
                    <count group_id="O3" value="87"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34" lower_limit="27.80" upper_limit="47.16"/>
                    <measurement group_id="O2" value="31" lower_limit="26.37" upper_limit="46.11"/>
                    <measurement group_id="O3" value="32" lower_limit="27.41" upper_limit="47.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (EOS) Good or Moderate</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="92"/>
                    <count group_id="O2" value="50"/>
                    <count group_id="O3" value="87"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59" lower_limit="53.95" upper_limit="73.18"/>
                    <measurement group_id="O2" value="50" lower_limit="46.98" upper_limit="67.33"/>
                    <measurement group_id="O3" value="63" lower_limit="62.23" upper_limit="80.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 52 EULAR score 'Good'. EULAR (European League Against Rheumatism) response was classified using the individual amount of change in the DAS28-CRP score. The 95% CIs for EULAR response rate and treatment difference were derived using the Wilson Score method.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference (%)</param_type>
            <param_value>1.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>7.19</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.59</ci_lower_limit>
            <ci_upper_limit>15.10</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 52 EULAR score 'Good'. EULAR (European League Against Rheumatism) response was classified using the individual amount of change in the DAS28-CRP score. The 95% CIs for EULAR response rate and treatment difference were derived using the Wilson Score method.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference (%)</param_type>
            <param_value>0.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>7.21</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.75</ci_lower_limit>
            <ci_upper_limit>14.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 52 EULAR score 'Good'. EULAR (European League Against Rheumatism) response was classified using the individual amount of change in the DAS28-CRP score. The 95% CIs for EULAR response rate and treatment difference were derived using the Wilson Score method.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference (%)</param_type>
            <param_value>-1.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>7.29</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-15.14</ci_lower_limit>
            <ci_upper_limit>12.91</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacodynamic Endpoint: Change From Baseline in Immunoglobulin (IgG, IgM and IgA Levels)</title>
        <description>Change from baseline (Day 1) in immunoglobulin G (IgG), Immunoglobulin M (IgM) and Immunoglobulin A (IgA) levels (mg/dL) at Week 8, 16, 24 36 and 52 (End of study)</description>
        <time_frame>Baseline (Day 1) and Weeks 8, 16, 24, 36 and 52 (EOS)</time_frame>
        <population>Pharmacodynamic Analysis Set (analyses are reported in terms of the arm that the patient was initially randomised into. In the Rituxan arm only, patients eligible for treatment in Part B underwent a second randomisation to receive either Rituxan or SAIT101 and are reported in the Rituxan arm according to their initial randomisation).</population>
        <group_list>
          <group group_id="O1">
            <title>SAIT101</title>
            <description>1000 mg intravenous (iv) SAIT101 on Day 1 and 15 (Part A). 1000 mg iv SAIT101 on week 24 and 26 (Part B) for eligible participants,</description>
          </group>
          <group group_id="O2">
            <title>MabThera</title>
            <description>1000 mg iv MabThera on Day 1 and 15 (Part A). 1000 mg iv MabThera on week 24 and 26 (Part B) for eligible participants.</description>
          </group>
          <group group_id="O3">
            <title>Rituxan</title>
            <description>1000 mg iv of Rituxan on Day 1 and 15 (Part A). 1000 mg iv of Rituxan on week 24 and 26 (Part B) for eligible participants</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacodynamic Endpoint: Change From Baseline in Immunoglobulin (IgG, IgM and IgA Levels)</title>
          <description>Change from baseline (Day 1) in immunoglobulin G (IgG), Immunoglobulin M (IgM) and Immunoglobulin A (IgA) levels (mg/dL) at Week 8, 16, 24 36 and 52 (End of study)</description>
          <population>Pharmacodynamic Analysis Set (analyses are reported in terms of the arm that the patient was initially randomised into. In the Rituxan arm only, patients eligible for treatment in Part B underwent a second randomisation to receive either Rituxan or SAIT101 and are reported in the Rituxan arm according to their initial randomisation).</population>
          <units>Mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="95"/>
                <count group_id="O2" value="96"/>
                <count group_id="O3" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IgG Screening</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="95"/>
                    <count group_id="O2" value="96"/>
                    <count group_id="O3" value="93"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1231.0" spread="299.36"/>
                    <measurement group_id="O2" value="1230.1" spread="365.54"/>
                    <measurement group_id="O3" value="1203.4" spread="373.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgG Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="94"/>
                    <count group_id="O2" value="94"/>
                    <count group_id="O3" value="91"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1108.0" spread="242.20"/>
                    <measurement group_id="O2" value="1080.6" spread="279.75"/>
                    <measurement group_id="O3" value="1038.5" spread="290.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgG Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="91"/>
                    <count group_id="O2" value="93"/>
                    <count group_id="O3" value="91"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1105.2" spread="232.51"/>
                    <measurement group_id="O2" value="1075.7" spread="277.51"/>
                    <measurement group_id="O3" value="1038.5" spread="290.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgG Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="91"/>
                    <count group_id="O2" value="83"/>
                    <count group_id="O3" value="86"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1114.6" spread="251.78"/>
                    <measurement group_id="O2" value="1077.2" spread="265.55"/>
                    <measurement group_id="O3" value="1023.2" spread="278.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgG Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="89"/>
                    <count group_id="O2" value="86"/>
                    <count group_id="O3" value="84"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1076.6" spread="246.62"/>
                    <measurement group_id="O2" value="1060.9" spread="305.12"/>
                    <measurement group_id="O3" value="976.6" spread="249.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgG Week 52 (EOS)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="89"/>
                    <count group_id="O2" value="86"/>
                    <count group_id="O3" value="87"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1102.0" spread="274.44"/>
                    <measurement group_id="O2" value="1081.1" spread="285.13"/>
                    <measurement group_id="O3" value="999.9" spread="232.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgM Screening</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="95"/>
                    <count group_id="O2" value="96"/>
                    <count group_id="O3" value="93"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="164.3" spread="76.07"/>
                    <measurement group_id="O2" value="167.9" spread="100.16"/>
                    <measurement group_id="O3" value="159.0" spread="81.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgM Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="94"/>
                    <count group_id="O2" value="94"/>
                    <count group_id="O3" value="91"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="137.5" spread="71.38"/>
                    <measurement group_id="O2" value="132.6" spread="83.58"/>
                    <measurement group_id="O3" value="128.9" spread="68.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgM Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="91"/>
                    <count group_id="O2" value="94"/>
                    <count group_id="O3" value="91"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="123.7" spread="61.08"/>
                    <measurement group_id="O2" value="124.9" spread="85.71"/>
                    <measurement group_id="O3" value="117.0" spread="60.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgM Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="91"/>
                    <count group_id="O2" value="86"/>
                    <count group_id="O3" value="86"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="123.3" spread="62.37"/>
                    <measurement group_id="O2" value="117.1" spread="80.96"/>
                    <measurement group_id="O3" value="109.9" spread="73.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgM Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="89"/>
                    <count group_id="O2" value="83"/>
                    <count group_id="O3" value="84"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="111.7" spread="56.89"/>
                    <measurement group_id="O2" value="108.0" spread="77.79"/>
                    <measurement group_id="O3" value="99.7" spread="56.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgM Week 52 (EOS)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="89"/>
                    <count group_id="O2" value="86"/>
                    <count group_id="O3" value="87"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109.6" spread="56.80"/>
                    <measurement group_id="O2" value="107.6" spread="77.00"/>
                    <measurement group_id="O3" value="95.2" spread="52.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgA Screening</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="95"/>
                    <count group_id="O2" value="96"/>
                    <count group_id="O3" value="93"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="321.1" spread="269.22"/>
                    <measurement group_id="O2" value="283.4" spread="134.80"/>
                    <measurement group_id="O3" value="342.9" spread="153.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgA Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="93"/>
                    <count group_id="O2" value="94"/>
                    <count group_id="O3" value="93"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="293.6" spread="176.04"/>
                    <measurement group_id="O2" value="264.4" spread="121.41"/>
                    <measurement group_id="O3" value="316.5" spread="146.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgA Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="91"/>
                    <count group_id="O2" value="93"/>
                    <count group_id="O3" value="91"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="301.8" spread="204.14"/>
                    <measurement group_id="O2" value="253.0" spread="111.58"/>
                    <measurement group_id="O3" value="312.7" spread="151.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgA Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="91"/>
                    <count group_id="O2" value="86"/>
                    <count group_id="O3" value="91"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="279.8" spread="119.87"/>
                    <measurement group_id="O2" value="263.0" spread="121.15"/>
                    <measurement group_id="O3" value="307.7" spread="147.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgA Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="89"/>
                    <count group_id="O2" value="83"/>
                    <count group_id="O3" value="89"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="283.8" spread="204.12"/>
                    <measurement group_id="O2" value="259.2" spread="116.55"/>
                    <measurement group_id="O3" value="297.1" spread="146.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgA Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="89"/>
                    <count group_id="O2" value="83"/>
                    <count group_id="O3" value="89"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="269.4" spread="116.74"/>
                    <measurement group_id="O2" value="254.7" spread="115.38"/>
                    <measurement group_id="O3" value="297.8" spread="138.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Pharmacodynamic Endpoint: Depletion of B-lymphocyte Antigen CD19 (CD19+) B-cell Count up to Week 24</title>
        <description>Pharmacodynamic endpoint: proportion of participants (n) with depletion of CD19+ B-cell count up to week 24 (Pharmacodynamic analysis set).</description>
        <time_frame>Samples for pharmacodynamic evaluation (CD19+ B-cell) were taken at Baseline and Weeks 0, 1, 2, 3, 4, 8, 12, 16, 20 and 24. Unscheduled visit samples were taken at the discretion of the investigator.</time_frame>
        <population>Pharmacokinetic data set</population>
        <group_list>
          <group group_id="O1">
            <title>SAIT101</title>
            <description>1000 mg intravenous (iv) SAIT101 on Day 1 and 15 (Part A). 1000 mg iv SAIT101 on week 24 and 26 (Part B) for eligible participants,</description>
          </group>
          <group group_id="O2">
            <title>MabThera</title>
            <description>1000 mg iv MabThera on Day 1 and 15 (Part A). 1000 mg iv MabThera on week 24 and 26 (Part B) for eligible participants.</description>
          </group>
          <group group_id="O3">
            <title>Rituxan</title>
            <description>1000 mg iv of Rituxan on Day 1 and 15 (Part A). 1000 mg iv of Rituxan on week 24 and 26 (Part B) for eligible participants</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacodynamic Endpoint: Depletion of B-lymphocyte Antigen CD19 (CD19+) B-cell Count up to Week 24</title>
          <description>Pharmacodynamic endpoint: proportion of participants (n) with depletion of CD19+ B-cell count up to week 24 (Pharmacodynamic analysis set).</description>
          <population>Pharmacokinetic data set</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="95"/>
                <count group_id="O2" value="96"/>
                <count group_id="O3" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="46"/>
                    <measurement group_id="O3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Pharmacodynamic Endpoint: Time Needed to CD19+ B-cell Depletion</title>
        <description>Time needed to CD19+ B-cell depletion in Part A (calculated as the first time CD19+ B-cell count below 20/µL minus time of first dosing in days).</description>
        <time_frame>Samples for pharmacodynamic evaluation (CD19+ B-cell) were taken at Baseline and Weeks 0, 1, 2, 3, 4, 8, 12, 16, 20, 24, 36 and 52. Unscheduled visit samples were taken at the discretion of the investigator.</time_frame>
        <population>Pharmacodynamic Analysis Set. Two participants in the SAIT101 arm, 3 participants in the MabThera arm and 3 participants in the Rituxan arm were excluded from the analysis either as they had a depleted C-cell count at baseline and / or if the Week 24 assessment was missing.</population>
        <group_list>
          <group group_id="O1">
            <title>SAIT101</title>
            <description>1000 mg intravenous (iv) SAIT101 on Day 1 and 15 (Part A). 1000 mg iv SAIT101 on week 24 and 26 (Part B) for eligible participants,</description>
          </group>
          <group group_id="O2">
            <title>MabThera</title>
            <description>1000 mg iv MabThera on Day 1 and 15 (Part A). 1000 mg iv MabThera on week 24 and 26 (Part B) for eligible participants.</description>
          </group>
          <group group_id="O3">
            <title>Rituxan</title>
            <description>1000 mg iv of Rituxan on Day 1 and 15 (Part A). 1000 mg iv of Rituxan on week 24 and 26 (Part B) for eligible participants</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacodynamic Endpoint: Time Needed to CD19+ B-cell Depletion</title>
          <description>Time needed to CD19+ B-cell depletion in Part A (calculated as the first time CD19+ B-cell count below 20/µL minus time of first dosing in days).</description>
          <population>Pharmacodynamic Analysis Set. Two participants in the SAIT101 arm, 3 participants in the MabThera arm and 3 participants in the Rituxan arm were excluded from the analysis either as they had a depleted C-cell count at baseline and / or if the Week 24 assessment was missing.</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="93"/>
                <count group_id="O2" value="93"/>
                <count group_id="O3" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.524" spread="2.6274"/>
                    <measurement group_id="O2" value="2.847" spread="9.1286"/>
                    <measurement group_id="O3" value="2.223" spread="9.0833"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Pharmacodynamic Endpoint: Duration of CD19+ B-cell Depletion</title>
        <description>Duration of CD19+ B-cell depletion (only participants that returned to non-depletion at or before week 24 were included)</description>
        <time_frame>Samples for pharmacodynamic evaluation (CD19+ B-cell) were taken at Baseline and Weeks 0, 1, 2, 3, 4, 8, 12, 16, 20, 24, 36 and 52. Unscheduled visit samples were taken at the discretion of the investigator.</time_frame>
        <population>Pharmacodynamic Analysis Set.Pharmacodynamic Analysis Set. Fifty seven participants in the SAIT101 arm, 70 participants in the MabThera arm and 72 participants in the Rituxan arm were excluded from the analysis either as they had a depleted C-cell count at baseline or if the Week 24 assessment was missing.</population>
        <group_list>
          <group group_id="O1">
            <title>SAIT101</title>
            <description>1000 mg intravenous (iv) SAIT101 on Day 1 and 15 (Part A). 1000 mg iv SAIT101 on week 24 and 26 (Part B) for eligible participants,</description>
          </group>
          <group group_id="O2">
            <title>MabThera</title>
            <description>1000 mg iv MabThera on Day 1 and 15 (Part A). 1000 mg iv MabThera on week 24 and 26 (Part B) for eligible participants.</description>
          </group>
          <group group_id="O3">
            <title>Rituxan</title>
            <description>1000 mg iv of Rituxan on Day 1 and 15 (Part A). 1000 mg iv of Rituxan on week 24 and 26 (Part B) for eligible participants</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacodynamic Endpoint: Duration of CD19+ B-cell Depletion</title>
          <description>Duration of CD19+ B-cell depletion (only participants that returned to non-depletion at or before week 24 were included)</description>
          <population>Pharmacodynamic Analysis Set.Pharmacodynamic Analysis Set. Fifty seven participants in the SAIT101 arm, 70 participants in the MabThera arm and 72 participants in the Rituxan arm were excluded from the analysis either as they had a depleted C-cell count at baseline or if the Week 24 assessment was missing.</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.444" spread="77.5290"/>
                    <measurement group_id="O2" value="85.856" spread="73.4460"/>
                    <measurement group_id="O3" value="77.290" spread="72.0557"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Pharmacodynamic Endpoint: Number of Participants With CD19+ B-cell Count Recover Versus Baseline</title>
        <description>Number of participants with CD19+ B-cell count recover versus baseline. Incidence of B-Cell recovery was defined as either CD19+ B-cell counts retuned to baseline or the lower limit or normal of 110 cells/µL at week 24).</description>
        <time_frame>Samples for pharmacodynamic evaluation (CD19+ B-cell) were taken at Baseline and Weeks 0, 1, 2, 3, 4, 8, 12, 16, 20, 24, 36 and 52. Unscheduled visit samples were taken at the discretion of the investigator.</time_frame>
        <population>Pharmacodynamic Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>SAIT101</title>
            <description>1000 mg intravenous (iv) SAIT101 on Day 1 and 15 (Part A). 1000 mg iv SAIT101 on week 24 and 26 (Part B) for eligible participants,</description>
          </group>
          <group group_id="O2">
            <title>MabThera</title>
            <description>1000 mg iv MabThera on Day 1 and 15 (Part A). 1000 mg iv MabThera on week 24 and 26 (Part B) for eligible participants.</description>
          </group>
          <group group_id="O3">
            <title>Rituxan</title>
            <description>1000 mg iv of Rituxan on Day 1 and 15 (Part A). 1000 mg iv of Rituxan on week 24 and 26 (Part B) for eligible participants</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacodynamic Endpoint: Number of Participants With CD19+ B-cell Count Recover Versus Baseline</title>
          <description>Number of participants with CD19+ B-cell count recover versus baseline. Incidence of B-Cell recovery was defined as either CD19+ B-cell counts retuned to baseline or the lower limit or normal of 110 cells/µL at week 24).</description>
          <population>Pharmacodynamic Analysis Set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="93"/>
                <count group_id="O2" value="93"/>
                <count group_id="O3" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Pharmaco Endpoint: Area Under the Concentration Time Curve of CD19 B-cell Count Change at Day 15 and Week 24</title>
        <description>Area under the concentration time curve of CD19 B-cell count change at Day 15 (AUEC0-d15) and week 24 (AUEC0-w24) based on change from baseline and percent of baseline values</description>
        <time_frame>Samples for pharmacodynamic evaluation (CD19+ B-cell) were taken at Baseline and Weeks 0, 1, 2, 3, 4, 8, 12, 16, 20, 24, 36 and 52. Unscheduled visit samples were taken at the discretion of the investigator.</time_frame>
        <population>Pharmacodynamic Analysis Set. AUC0-d15 could not be determined for 23 participants in the SAIT101 arm, 20 participants in the MabThera arm and 20 participants in the Rituxan arm as either the baseline data was missing and /or there was a missing b-cell could at the last timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>SAIT101</title>
            <description>1000 mg intravenous (iv) SAIT101 on Day 1 and 15 (Part A). 1000 mg iv SAIT101 on week 24 and 26 (Part B) for eligible participants,</description>
          </group>
          <group group_id="O2">
            <title>MabThera</title>
            <description>1000 mg iv MabThera on Day 1 and 15 (Part A). 1000 mg iv MabThera on week 24 and 26 (Part B) for eligible participants.</description>
          </group>
          <group group_id="O3">
            <title>Rituxan</title>
            <description>1000 mg iv of Rituxan on Day 1 and 15 (Part A). 1000 mg iv of Rituxan on week 24 and 26 (Part B) for eligible participants</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmaco Endpoint: Area Under the Concentration Time Curve of CD19 B-cell Count Change at Day 15 and Week 24</title>
          <description>Area under the concentration time curve of CD19 B-cell count change at Day 15 (AUEC0-d15) and week 24 (AUEC0-w24) based on change from baseline and percent of baseline values</description>
          <population>Pharmacodynamic Analysis Set. AUC0-d15 could not be determined for 23 participants in the SAIT101 arm, 20 participants in the MabThera arm and 20 participants in the Rituxan arm as either the baseline data was missing and /or there was a missing b-cell could at the last timepoint.</population>
          <units>cells*day/µL)</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUEC(0-d15)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="72"/>
                    <count group_id="O2" value="76"/>
                    <count group_id="O3" value="73"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2650.0" lower_limit="-2786.0" upper_limit="-2513.9"/>
                    <measurement group_id="O2" value="-2672.1" lower_limit="-2804.9" upper_limit="-2539.3"/>
                    <measurement group_id="O3" value="-2719.4" lower_limit="-2855.3" upper_limit="2583.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUEC(0-w24)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="56"/>
                    <count group_id="O3" value="52"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-32707.6" lower_limit="-33128.1" upper_limit="-32287.1"/>
                    <measurement group_id="O2" value="-33018.3" lower_limit="-33440.4" upper_limit="-32596.2"/>
                    <measurement group_id="O3" value="-33003.7" lower_limit="-33442.8" upper_limit="-32564.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The statistical comparison of the between treatments is based on an analysis of covariance (ANOVA) model with fixed effect for treatment and a covariate for baseline value.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Statistical comparison of CD19+ B-cell pharmacokinetic parameters at Day 15 [AUEC(0-d15)]</non_inferiority_desc>
            <param_type>Statistical Comparisons Difference</param_type>
            <param_value>22.1</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-137.1</ci_lower_limit>
            <ci_upper_limit>181.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The statistical comparison of the between treatments is based on an analysis of covariance (ANOVA) model with fixed effect for treatment and a covariate for baseline value.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Statistical comparison of CD19+ B-cell pharmacokinetic parameters at Day 15 [AUEC(0-d15)]</non_inferiority_desc>
            <param_type>Statistical Comparisons Difference</param_type>
            <param_value>69.5</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-91.8</ci_lower_limit>
            <ci_upper_limit>230.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The statistical comparison of the between treatments is based on an analysis of covariance (ANOVA) model with fixed effect for treatment and a covariate for baseline value.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Statistical comparison of CD19+ B-cell pharmacokinetic parameters at Day 15 [AUEC(0-d15)]</non_inferiority_desc>
            <param_type>Statistical Comparisons Difference</param_type>
            <param_value>47.4</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-112.5</ci_lower_limit>
            <ci_upper_limit>207.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The statistical comparison of the between treatments is based on an analysis of covariance (ANOVA) model with fixed effect for treatment and a covariate for baseline value.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Statistical comparison of CD19+ B-cell pharmacokinetic parameters at Day week [AUEC(0-w24)]</non_inferiority_desc>
            <param_type>Statistical Comparisons Difference</param_type>
            <param_value>310.7</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-187.9</ci_lower_limit>
            <ci_upper_limit>809.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The statistical comparison of the between treatments is based on an analysis of covariance (ANOVA) model with fixed effect for treatment and a covariate for baseline value.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Statistical comparison of CD19+ B-cell pharmacokinetic parameters at Day week [AUEC(0-w24)]</non_inferiority_desc>
            <param_type>Statistical Comparisons Difference</param_type>
            <param_value>296.1</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-213.8</ci_lower_limit>
            <ci_upper_limit>806.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The statistical comparison of the between treatments is based on an analysis of covariance (ANOVA) model with fixed effect for treatment and a covariate for baseline value.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Statistical comparison of CD19+ B-cell pharmacokinetic parameters at Day week [AUEC(0-w24)]</non_inferiority_desc>
            <param_type>Statistical Comparisons Difference</param_type>
            <param_value>-14.6</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-527.4</ci_lower_limit>
            <ci_upper_limit>498.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Pharmacodynamic Endpoint: Change From Baseline in CD19+ B-cell Count During the Study Period</title>
        <description>Pharmacodynamic endpoint: Descriptive statistics (mean [SD]) of the change from baseline in CD19+ B-cell count during the study period (Day 15 [AUEC(0-d15] and Week 24 [AUEC(0-w24])</description>
        <time_frame>Samples for pharmacodynamic evaluation (CD19+ B-cell) were taken at Baseline and Weeks 0, 1, 2, 3, 4, 8, 12, 16, 20 and 24. Unscheduled visit samples were taken at the discretion of the investigator.</time_frame>
        <population>Pharmacodynamic Analysis Set. participants in the SAIT101 arm, Twenty three participants in the MabThera arm, 20 participants in the MabThera and 20 participants in the Rituxan arm were excluded from the analysis either as they had a depleted C-cell count at baseline and / or the Week 24 assessment was missing.</population>
        <group_list>
          <group group_id="O1">
            <title>SAIT101</title>
            <description>1000 mg intravenous (iv) SAIT101 on Day 1 and 15 (Part A). 1000 mg iv SAIT101 on week 24 and 26 (Part B) for eligible participants,</description>
          </group>
          <group group_id="O2">
            <title>MabThera</title>
            <description>1000 mg iv MabThera on Day 1 and 15 (Part A). 1000 mg iv MabThera on week 24 and 26 (Part B) for eligible participants.</description>
          </group>
          <group group_id="O3">
            <title>Rituxan</title>
            <description>1000 mg iv of Rituxan on Day 1 and 15 (Part A). 1000 mg iv of Rituxan on week 24 and 26 (Part B) for eligible participants</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacodynamic Endpoint: Change From Baseline in CD19+ B-cell Count During the Study Period</title>
          <description>Pharmacodynamic endpoint: Descriptive statistics (mean [SD]) of the change from baseline in CD19+ B-cell count during the study period (Day 15 [AUEC(0-d15] and Week 24 [AUEC(0-w24])</description>
          <population>Pharmacodynamic Analysis Set. participants in the SAIT101 arm, Twenty three participants in the MabThera arm, 20 participants in the MabThera and 20 participants in the Rituxan arm were excluded from the analysis either as they had a depleted C-cell count at baseline and / or the Week 24 assessment was missing.</population>
          <units>Cells*day/µL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUEC(0-d15)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="72"/>
                    <count group_id="O2" value="76"/>
                    <count group_id="O3" value="73"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2729" spread="1915.3"/>
                    <measurement group_id="O2" value="-2935" spread="2222.1"/>
                    <measurement group_id="O3" value="-2367" spread="1978.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUEC(0-w24)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="56"/>
                    <count group_id="O3" value="52"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-33500" spread="23881"/>
                    <measurement group_id="O2" value="-36410" spread="22883"/>
                    <measurement group_id="O3" value="-28500" spread="20878"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Pharmacodynamic Endpoint: Change From Baseline in C-reactive Protein (CRP) Levels at Weeks 8, 16, 24, 36 and 52</title>
        <description>Pharmacodynamic endpoint: Change from baseline (Day 1) in C-reactive protein (CRP) levels (mg/dL) at weeks 8, 16, 24, 36 and 52 (EOS)</description>
        <time_frame>Baseline (Day 1) and Weeks 8, 16, 24, 26 &amp; 52 (EOS)</time_frame>
        <population>Pharmacodynamic Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>SAIT101</title>
            <description>1000 mg intravenous (iv) SAIT101 on Day 1 and 15 (Part A). 1000 mg iv SAIT101 on week 24 and 26 (Part B) for eligible participants,</description>
          </group>
          <group group_id="O2">
            <title>MabThera</title>
            <description>1000 mg iv MabThera on Day 1 and 15 (Part A). 1000 mg iv MabThera on week 24 and 26 (Part B) for eligible participants.</description>
          </group>
          <group group_id="O3">
            <title>Rituxan</title>
            <description>1000 mg iv of Rituxan on Day 1 and 15 (Part A). 1000 mg iv of Rituxan on week 24 and 26 (Part B) for eligible participants</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacodynamic Endpoint: Change From Baseline in C-reactive Protein (CRP) Levels at Weeks 8, 16, 24, 36 and 52</title>
          <description>Pharmacodynamic endpoint: Change from baseline (Day 1) in C-reactive protein (CRP) levels (mg/dL) at weeks 8, 16, 24, 36 and 52 (EOS)</description>
          <population>Pharmacodynamic Analysis Set</population>
          <units>Mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="95"/>
                <count group_id="O2" value="96"/>
                <count group_id="O3" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CRP Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.5" spread="29.50"/>
                    <measurement group_id="O2" value="15.5" spread="20.76"/>
                    <measurement group_id="O3" value="16.1" spread="17.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CRP Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5" spread="15.78"/>
                    <measurement group_id="O2" value="12.3" spread="20.29"/>
                    <measurement group_id="O3" value="10.4" spread="12.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CRP Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.5" spread="11.78"/>
                    <measurement group_id="O2" value="7.2" spread="9.02"/>
                    <measurement group_id="O3" value="7.3" spread="6.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CRP Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.5" spread="14.54"/>
                    <measurement group_id="O2" value="8.3" spread="14.40"/>
                    <measurement group_id="O3" value="7.9" spread="10.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CRP Week 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0" spread="10.33"/>
                    <measurement group_id="O2" value="7.0" spread="10.38"/>
                    <measurement group_id="O3" value="7.1" spread="9.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CRP Week 52 (EOS)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.8" spread="14.28"/>
                    <measurement group_id="O2" value="9.1" spread="15.01"/>
                    <measurement group_id="O3" value="7.3" spread="11.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>After the participant signed the Informed Consent Form (ICF), but prior to the initiation of study drug, only Serious Adverse Events (SAEs) caused by a protocol mandated procedure should be reported (e.g. SAEs related to invasive procedures such s biopsies). All adverse events were collected for each patient from the start of the first infusion of study drug on Day 1 until the Week 52 Data-cut off.</time_frame>
      <desc>Safety Analysis Set (analyses are reported in terms of the arm that the patient was initially randomised into. In the Rituxan arm only, patients eligible for treatment in Part B underwent a second randomisation to receive either Rituxan or SAIT101 and are reported in the Rituxan arm according to their initial randomisation).</desc>
      <group_list>
        <group group_id="E1">
          <title>SAIT101</title>
          <description>SAIT101: 1,000 mg i.v. of SAIT101 on Day 1 and 15. 1,000 mg i.v. of SAIT101 on week 24 and 26 for eligible participants.</description>
        </group>
        <group group_id="E2">
          <title>MabThera</title>
          <description>MabThera: 1,000 mg i.v. of MabThera® on Day 1 and 15. 1,000 mg i.v. of MabThera® on week 24 and 26 for eligible participants.</description>
        </group>
        <group group_id="E3">
          <title>Rituxan</title>
          <description>Rituxan: 1,000 mg i.v. of Rituxan® on Day 1 and 15. 1,000 mg i.v. of Rituxan® on week 24 and 26 for eligible participants.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (21.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="98"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="98"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Hepatitis B</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Hepatitis B reactivation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Herpes simplex</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Meningitis bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Subdural hematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Oseoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Renal cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory distress</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (21.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="98"/>
                <counts group_id="E3" subjects_affected="43" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="98"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="98"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="98"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="14" subjects_affected="13" subjects_at_risk="98"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="98"/>
                <counts group_id="E3" events="10" subjects_affected="8" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="98"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="98"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="98"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="98"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="98"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="98"/>
                <counts group_id="E3" events="8" subjects_affected="7" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="98"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="98"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="98"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="98"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director</name_or_title>
      <organization>Archigen Biotech Ltd</organization>
      <phone>+44(0)20 3749 5000</phone>
      <email>info@archigenbio.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

